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Diet quality plays a role in progressive physical, as well as mental, co-morbidities, 
particularly among those with elevated weight status. Therefore, research exploring cost-effective, 
practical, and sustainable strategies to promote healthy weight status as well as healthy cognitive 
and mental health status are of great interest to public health agencies and individuals alike. Dietary 
intake as well as serum and cortical accumulation of the dietary components lutein and choline 
have been linked with benefits for cognition across the lifespan. This Dissertation work utilized 
three aims to investigate the impact of both independent and interactive dietary consumption and 
biomarker concentrations of these components in a young-to-middle aged sample of adults with 
overweight or obesity. Aim 1 utilized a cross-sectional sample as well as a randomized controlled 
trial to examine the impact of dietary, serum, and retinal lutein concentrations on cognitive control. 
Aim 2 examined the impact of dietary choline intake on cognitive control. Lastly, Aim 3 examined 
the interactive nature of dietary intake of lutein and choline, serum lutein concentrations, and 
choline metabolites on cognitive control. 
Methods 
The Persea Americana for Total Health (PATH) Study was a 12-week randomized 
controlled trial aimed at assessing the impact of avocado consumption on primary outcomes of 
visceral adiposity and glycemic control. Secondary outcomes analyzed within this work were 
behavioral and neuroelectric indices of cognitive control, specifically selective attention, response 
inhibition, and cognitive flexibility. Adults with overweight and obesity (Body Mass Index [BMI] 
≥ 25.0]) between the ages of 25-45 years completed 7-day diet records, venous blood draws, 




Kaufman Brief Intelligence Test–2 (IQ), the Eriksen Flanker task, Oddball/No-go task, and a 
Switch task while undergoing electroencephalographic recording for event-related potential 
extraction (ERP). For intervention analyses, participants were randomized to a treatment group 
(N = 47) that received a 12-week daily meal with fresh Hass avocado or a control group (N = 37) 
that received an isocaloric meal (clinicaltrials.gov, NCT02740439). Baseline data, prior to 
randomization, was utilized for cross-sectional analyses. Cognitive outcomes included behavioral 
(accuracy and reaction time [RT]) as well as the N2 and P3 ERP components. 
Results 
Aim 1-a utilized partial correlations between MPOD and behavioral and neuroelectric 
outcomes of an Oddball Task to examine the impact of retinal xanthophyll accumulation (MPOD) 
on cognitive control. These cross-sectional analyses revealed that after controlling for sex and 
dietary lutein/zeaxanthin intake, higher MPOD was associated with lower N2 mean amplitude 
(ρ=−0.21, p=0.04) and P3 peak latency (ρ=−0.27, p<0.01) during target trials, as well as lower P3 
peak amplitude (ρ=−0.22, p=0.03) during standard trials. Improvements in behavioral outcomes 
were not observed (all p’s > 0.05).  
Aim 1-b utilized intervention data from the PATH study to examine the impact of 12-week 
avocado consumption on behavioral and neuroelectric outcomes of a modified Eriksen Flanker, 
Oddball, and No-go task. These analyses revealed significant time x group interactions 
(F(1,79) = 26.98, p < 0.001, ηp
2 = 0.26) for serum lutein concentrations as well improvements in 
accuracy in both the congruent (change: 1.3%, p=0.05; 95% CI:−3.02 to 2.3) and incongruent 
(change: 3.0%, p< 0.01; 95%CI: 1.1 to 5.0) Flanker task conditions, indicating that the group 




improvement on a selective attention task. Improvements in MPOD, on other cognitive tasks, and 
neuroelectric indices of cognitive outcomes were not observed (all p’s>0.05). 
Aim 2 utilized hierarchical linear regression analyses to examine the impact of dietary 
choline intake on behavioral and neuroelectric outcomes of a modified Eriksen Flanker Task. 
These cross-sectional analyses revealed that after controlling for age, sex, BMI, IQ, and overall 
diet quality, higher choline intake was associated with lower P3 peak amplitude (β=−0.25, p <0.01) 
during incongruent trials. Relationships with behavioral outcomes were not observed (all 
p’s>0.05). 
Aim 3 examined the independent and potentially interactive effects of dietary lutein, 
dietary choline, serum lutein concentrations, MPOD, plasma phosphatidylcholine (PC) and free 
choline concentrations on cognitive control. These analyses utilized hierarchical linear regression 
analyses controlling for sex, age, IQ, BMI, and household income. A multiplicative interaction 
term of dietary lutein and dietary choline intake improved models for RT in all trials of a cognitive 
flexibility task: NonSwitch RT (ΔR²=0.10 p=0.03), Switch RT (ΔR²=0.10 p=0.05), and Global 
Switch Cost (ΔR²=0.08 p=0.05) during the switch task. Plasma PC independently was associated 
with accuracy during a Switch task (β=0.24, p=0.04). 
Conclusion 
The dietary components lutein and choline have been hypothesized to play a protective role 
in cognitive health across the lifespan. This dissertation work demonstrated that independent as 
well as interactive consumption of both lutein and choline was associated with neurocognitive 
benefits for adults with overweight or obesity in middle-adulthood. This work represents additional 
evidence suggesting that foods high in lutein and choline may offer neuroprotective effects among 
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CHAPTER 1: INTRODUCTION 
 
Recent work demonstrates that diet quality throughout the United States continuously fails 
to meet current dietary recommendations1. This is concerning, as diet quality has been 
demonstrated to play a role in progressive physical, as well as mental, co-morbidities. Currently, 
national dietary recommendations are developed based on comprehensive evidence for prevention 
of physical health related outcomes, with minimal consideration of the importance of diet quality 
for cognitive and mental health. Elucidation of the particular role of nutrient consumption on 




While improvements in diet quality and nutrient intake are recommended to all individuals, 
individuals with overweight and obesity may benefit disproportionately from these proposed 
dietary improvements. Defined as having a body mass index (BMI; kg/m2) greater than or equal 
to 25.0, individuals with overweight and obesity are at higher risk of exhibiting deficits in 
cognition, particularly cognitive control, than their healthy weight peers, particularly during 
middle-adulthood2. Additionally, elevated weight status during middle-adulthood has been linked 
with a potential 35% increased risk of dementia in individuals with overweight, and 74% increased 
risk in individuals with obesity3. Intriguingly, these deficits in cognitive function have been 
observed independent of obesity’s clinical co-morbidities such as type 2 diabetes, alterations in 
glycemic control, and metabolic risk factors4. Therefore, research exploring cost-effective, 
practical, and sustainable strategies to promote healthy weight status as well as healthy cognitive 
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The work herein focuses on two particular dietary components of interest, the xanthophyll 
carotenoid lutein, and the vitamin-like component choline. Recent work has identified potential 
physical as well as cognitive benefits from increased consumption of these dietary components, 
but this work has yet to be done within a sample of adults with overweight or obesity. Therefore 
outlined in this dissertation are four examinations of the potential impact of dietary intake as well 
as biomarker concentrations of lutein and choline on cognitive control in young to middle aged 















CHAPTER 2: REVIEW OF KEY LITERATURE 
Neurocognitive outcomes of cognitive control as a target for nutrition interventions in adults with 
overweight and obesity 
Cognitive control, also known as executive function, is comprised of a set of interrelated, 
yet dissociable, higher order processes including inhibition (the ability to resist distractions and 
maintain attention), response inhibition (the ability to inhibit responses to stimuli), and cognitive 
flexibility (the ability to dynamically shift attention and alter response strategy to changing 
demands)5. These processes allow for the ability to interact with, as opposed to merely respond to, 
salient stimuli in our surrounding environments.  
 
Cognitive control is frequently examined using tasks designed to assess behavioral 
outcomes such as accuracy and reaction time (RT). These behavioral outcomes have been 
demonstrated to be beneficially associated with aerobic activity and diet in human populations6–8. 
While these behavioral benefits have been observed, further explanation of underlying inducting 
mechanisms of these benefits have been far less examined. Utilizing electroencephalographic 
(EEG) recording of neuroelectric potentials time-locked to task stimuli (event-related potentials 
[ERPs]) allows for exploration of the underlying neural mechanisms of mental chronometry 
potentially responsible for observed behavioral differences. EEG can reflect changes in cognitive 
effort irrespective of changes in performance. Specifically, potentials emitted at the level of the 
scalp can be used to quantify the magnitude of resources required (amplitude) and speed of 
processing necessary for cognitive processes (latency). In comparison to other currently available 
neuroimaging techniques, ERPs are considered the gold standard of temporal resolution. ERPs 
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allow for examination of ongoing brain activity with no delay, and studies have examined ERP 
potentials as early as 20ms post-stimulus onset. 
 
Examination of responses to stimuli is made possible through the extraction of outcomes 
referred to as ERP components. An ERP component is defined as a voltage deflection that is 
produced when a specific neural process occurs in a specific brain region. Each task stimuli elicits 
a number of components, and when summed together, the components produce an ERP waveform 
(Figure 2.1)9. Two components of interest in the present work are the N200 (N2) and the P300 
(P3, P3b). The N2 is a negative-going potential occurring approximately 200ms post-stimulus 
onset and is an index of response inhibition. The P300 (P3, P3b) is a positive-going potential 
occurring between 300-700ms post-stimulus onset as an index of context updating, resource 
allocation, and categorization9. Longer latencies of the N2 and the P3 in response to visual stimuli 
have been positively associated with cognitive decline, with potential amelioration with positive 
health behaviors such as a healthy diet10. Utilizing ERPs in conjunction with behavioral responses 
to explore the associations of dietary intake and biomarker concentrations may therefore explicate 
the dietary derived cognitive benefits previously observed in behavioral outcomes. Both latency 
and amplitude of the N2 and P3 component have been associated with weight status, and it has 
been demonstrated that individuals with overweight or obesity display larger N2 and P3 amplitudes 










 When interpreting ERP components, neural efficiency provides an explanation for 
differences observed. The neural efficiency hypothesis was first introduced by Haier et al. in 
198813. In work utilizing utilized positron emission tomography Haier and colleagues observed 
that “for normal young adults for whom a cognitive task is difficult, more cortical activity 
throughout the brain is necessary to perform the task.” They postulated that among the individuals 
who performed worse on an abstract reasoning test, this recruitment of additional resources may 
be due to the inappropriate use of excess energy by each neuron and/or use of more neurons to 
perform the task. The result is thus an increase in cognitive resources utilized, lower task 
performance, and an overall inefficient approach to completing the task at hand. This theory has 
been thus replicated using EEG methodology. Neubauer et. al. report that in a Figure-spatial Posner 
task, those with higher figural-spatial ability need less brain activation to carry out a task and that 
task performance in brighter individuals is accompanied by a stronger increase in short-range 
communication between adjacent brain regions14. This implies that efficient brain activation could 
be the result of better functional coupling of short-range connections14. In the context of the ERP, 
there is general consensus that both the amplitude and latency of the N2 and P3 components can 
Figure 2.1. An example depiction 
of the time course of Event-
Related Potentials post-stimulus 
onset (0 ms).  
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be utilized as endogenous measures of processing efficiency. Latency, or onset of an ERP 
component, reflects the timing of mental processes. A decreased/faster latency on a task would 
therefore imply more efficient processing. Peak amplitude, or the largest deviation from baseline 
during the time-frame of a chosen component, reflects the intensity of processing. A larger peak 
amplitude in comparison to a smaller peak amplitude would imply the need for recruitment of 
additional resources15. 
 
Lutein and Zeaxanthin 
Lutein and zeaxanthin belong to the carotenoid class of dietary components. Carotenoids 
are plant pigments found in green leafy vegetables as well as eggs and avocados. Specifically, 
lutein and zeaxanthin are polar, oxygenated carotenoids referred to as xanthophylls.  Lutein and 
zeaxanthin accumulate in many areas throughout the body, including but not limited to skin, 
adipose tissue, and serum, and they are able to cross the blood-brain interface to preferentially 
deposit within the macula of the eye and the brain16. Lutein is the predominant carotenoid in the 
human brain, with levels in the infant brain comprising ~59% of total carotenoids, and levels in 
octogenarian brain samples comprising ~34% of total carotenoids17,18. Lutein, alongside 
zeaxanthin and its retinal stereo-isomer, meso-zeaxanthin, accumulates in an extension of the 
central nervous system, the macula of the eye. Therefore, Macular Pigment Optical Density 
(MPOD), or retinal accumulation as an extension of brain accumulation, can be assessed using the 
validated and non-invasive measure of heterochromatic flicker photometry19. MPOD levels are 
closely correlated to xanthophyll concentrations found in pediatric and geriatric human retina and 
brain samples, substantiating their status as biomarkers of retinal and neural tissue xanthophyll 
accumulation20,21. Lutein quantification may also be done through serum samples. Serum lutein 
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may serve as a transient site of lutein until it is further able to be stored in peripheral tissues, and 
serum lutein may be a better marker of acute dietary lutein intake, while brain or retinal 
accumulation may be a better representation of chronic lutein intake18. 
Carotenoids, including xanthophylls, are not synthesized de novo, and thus, humans must 
consume them from dietary sources in order to facilitate bodily accumulation. While a host of 
modifiable and non-modifiable factors may influence rate of lutein accumulation, as the human 
body is incapable of xanthophyll synthesis, levels quantified in bodily tissue are attributable to 
dietary intake16. Lutein and zeaxanthin are polar, lipophilic molecules, most commonly found in 
plants such as fruits and vegetables, avocados, and egg yolks22. Zeaxanthin, lutein’s structural 
isomer, is derived from similar food items, and thus lutein and zeaxanthin quantification from 
foods is aggregated in most nutrient databases. As the work herein utilized dietary records to assess 
xanthophyll intake, lutein and zeaxanthin will be cumulatively referred to as dietary lutein 
throughout. 
 
Lutein and Cognition 
The eye is an extension of the neural system, and research has highlighted a role between 
visual health and cognitive health23–25. Similarly, macular pigmentation, or MPOD, is 
hypothesized to play a role in cognitive and mental health26. Previous work performed by our 
laboratory and others has indicated that higher accumulation of neural lutein – as assessed through 
retinal MPOD– is associated with cognition across the lifespan – with studies in childhood, young-
to-middle adulthood, and older adulthood27–30. While mechanistic explanations for these 
relationships are thus far sparse, theories point towards lutein’s role in increased neural processing 
speed and improved efficiency of attentional resource facilitation31. Post-receptorally, lutein and 
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zeaxanthin are hypothesized to play various neuroprotective roles across the lifespan, possibly as 
antioxidants and anti-inflammatory agents. The brain has a high oxygen demand and is comprised 
of a large number of polyunsaturated fatty acids, thus making it particularly susceptible to 
oxidative damage. While the exact mechanisms of xanthophylls cognitive benefits are yet to be 
understood, it is widely accepted that the main role in the eye of retinal accumulation of 
xanthophylls is antioxidant, and anti-inflammatory32–34. As levels in the retina and the brain have 
been demonstrated to be related, a likely theory is that xanthophylls in the brain play a role similar 
to their role in the retina. Additional support for xanthophylls role in inflammation draws from 
work in individuals with cardiovascular disease, and reports that xanthophyll status is inversely 
related with circulating inflammatory markers such as c-reactive protein and interleukin-635,36. As 
decrements in cognition have been linked with increased oxidative damage and inflammation, it is 
likely that lutein is a pertinent neuroprotective agent in this context37. Another theory for the 
mechanism of xanthophyll action in the brain surrounds brain integrity38. Loss of white matter 
integrity has been associated with a reduction in processing speed. This loss in in integrity has also 
been associated with age, as well as diet. Supplementation of xanthophylls may thus promote 
increased brain integrity, facilitating neural efficiency. 
 
Choline 
Intake of choline, a vitamin-like water-soluble nutrient, has been linked to cognitive 
improvements in human populations among both perinatal and geriatric populations39. Humans 
are capable of de novo choline biosynthesis through the phosphatidylethanolamine N-
methyltransferase pathway, albeit in concentrations that are insufficient to maintain many 
biological processes40. Thus, it is imperative that choline be consumed through diet. Common 
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foods rich in choline include eggs (147 mg/serving), soybeans (107 mg/serving), chicken breast 
(72 mg/serving), and beef (72 mg/serving). The Institute of Medicine recommends an Adequate 
Intake (AI) for choline of 425 mg/d for women and 550 mg/day for men41. However, 90% of the 
US population does not meet this AI recommendation41. Choline is vital for neurotransmitter 
synthesis (as the precursor to acetylcholine [ACh]), cell-membrane integrity and signaling function 
(through phosphatidylcholine [PC]), and methyl-donor metabolism (through the conversion of 
methionine to homocysteine), and lipid-cholesterol transport and metabolism39,42. Higher choline 
intake has also been associated with lower whole body %fat and higher levels of lean mass amongst 
both animal and clinical models43. Choline plays a vital role in central nervous system development 
and choline supplementation has been shown to benefit memory and brain development in human 
and pre-clinical models44. Phosphatidylcholine is the most prevalent form of choline in the body 
and it forms essential structural components of cell membranes and myelin sheaths throughout the 
brain and the body.  
 
Choline and Cognition 
Choline plays a vital role in central nervous system development. Investigation into the 
proposed mechanisms of action for choline and its related metabolites for cognitive performance 
and maintenance are ongoing. Theories include: choline’s role as a methyl donor, and through 
DNA methylation, potential modulation of expression of genes involved in learning and memory 
processing, prevention against the pathogenetic phospholipid defects potentially specific to AD, 
and choline’s indirect reduction of plasma homocysteine concentrations45,46. Circulating PC 
concentrations have been found to be lower in patients with AD, and alterations in peripheral and 
brain PC/lipid metabolism among patients with AD have been demonstrated47,48. Adequate 
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concentrations of choline in the brain are believed to protect against age-related cognitive decline 
and certain types of dementia46. These findings allude to a potential benefit of circulating PC for 
cognitive health, though testing of this relationship has been problematic due to heterogeneity of 
both results and testing methods. In elderly patients with AD, higher concentrations of free choline 
have been observed within the brain49. These higher concentrations of free choline have been 
interpreted as a marker of neurodegeneration, in what has been referred to as “autocannabalism” 
– or the brains degenerating attempts to release choline from its largest storage site (PC) and 
compensate for the characteristic lack of free choline and ACh49. Much of current AD treatment is 
based around this choline deficit, through the use of cholinergic agonists to promote choline 
production and preserve cell membrane integrity50. 
 
Regardless, much evidence for the imperative role of choline in brain development begins 
with prenatal development. Rodent research has demonstrated that rats born to choline-deficient 
mothers have alterations to hippocampal structure and function51,52. Similar results have been 
shown in the piglet model, perhaps the animal model closest anatomically as well as 
physiologically to the human brain. Piglets born to sows on choline-deficient diets have been found 
to exhibit decreased total brain volume when compared to piglets born from choline-sufficient 
sows53. These findings have been mirrored in recent human work as well. The closest replication 
of this animal work is evidenced through the Project Viva Study. Two iterations of literature have 
emerged from this largescale longitudinal study – one at years 3 of age and another at age 7. At 
age 3, there was no observed relationship between maternal choline intake and cognitive outcomes, 
yet at age 7 higher maternal choline intake was associated with improved visual memory54,55. 
Published work conducted in other age groups suggests that high choline intake as well as choline 
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supplementation has benefits for memory and brain development, and higher phosphatidylcholine 
(PC) intake has been found to be associated with a lower risk of dementia56. In the Framingham 
Offspring Study, Poly et al. reported that middle-aged, healthy individuals (mean age = 60.1 years) 
with higher choline consumption five years prior to fMRI testing showed an inverse relationship 
with choline intake and White Matter Hyperintensity (WMH), an associated marker of cognitive 
impairment and Alzheimer’s Disease46. As white matter integrity has been associated with greater 
performance on cognitive variables such as reading, IQ, information processing, and attention, this 
again points to the neuroprotective role of choline in the neocortex across the lifespan57. WMH 
has also been inversely associated with obesity, in particular, the metabolically active visceral 
adiposity has been positively associated with the increased presence of WMH58. As choline intake 
has also been shown to be inversely related to whole body %fat positively associated with higher 
levels of lean mass, increasing choline intake may be of particular importance to individuals with 
overweight or obesity. 
 
Choline and lipid production 
Beyond the direct role of choline on ACh in the brain, choline acts as a regulator of hepatic 
lipid secretion. In animal studies, choline deficiency has been shown to induce fatty liver within 
hours of diet initiation59. PC is necessary to form lipoprotein particles (particularly VLDL and 
LDL), and with insufficient dietary intake of choline, PC is not capable of being produced in 
quantities able to support lipoprotein synthesis. Thus, consequences are two-fold: there is 
intracellular accumulation of triglycerides within hepatic cells, and there is diminished transport 
of dietary components carried throughout the body on lipoproteins. One such dietary component 




Nutrient Interaction vs. Association 
 While comparably greater progress has been made in identifying single-nutrient benefits 
on cognitive health, research has presently frequently failed to take into account the interactive 
action and metabolism of nutrient combinations. It is not likely that the benefits of nutrition for 
cognitive health and cognitive decline are solely the result of small and summative independent 
nutrients. Determination of beneficial interactive potential may help inform food and dietary 
pattern level recommendations. Theoretically, and statistically, untangling the independent versus 
interactive impacts of nutrients though has been problematic. The term interactive means “when 
the effect of one explanatory variable depends on the particular level or value of another 
explanatory variable.” In comparison, the term association means “information about the value of 
one variable conveys information about the average value of another variable60.” Put more simply, 
an interaction would be examining if the cognitive benefit of consuming high amounts of lutein is 
greater when consuming higher amounts of choline, or vice versa61. 
 
Potential interactive effects of lutein and choline 
While current trends in research have explored the impact of single-nutrient intake on 
measures of physical and mental health, nutrients are not often consumed in isolation. Recent 
evidence has supported the beneficial role of nutrition in cognitive health, yet explanations of mode 
of delivery for nutrition are varied. The majority of nutrition research has focused on either the 
impact of a single nutrient or an entire food-source on physical, mental, and social health outcomes. 
The gap between these two methodologies is vast, and leaves many questions unanswered about 
the potential interactive capabilities of dietary components and whole food-sources on health 
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related outcomes, particularly those cognitively-related. If nutrition is to be utilized as a means of 
cognitive maintenance and prevention of cognitive decline, further examination of these 
interactive capabilities is necessary. 
One reason for identification of the potential interactions of lutein and choline is drawn 
from collaborative roles in absorption and circulation. To promote the bioavailability of 
xanthophylls, most randomized controlled trials promote consumption of lutein with a source of 
fat. Without a fatty matrix for the xanthophyll to adhere to, there is significantly decreased 
absorption62. Much work has explored the impact of phospholipid (PL) type on absorption of 
carotenoids in vitro and in vivo. These studies have focused on PC and its hydrolyzed isomer, lyso-
phosphatidylcholine (LysoPC). Within the small intestine, LysoPC is produced by reversible 
hydrolysis of PC by the pancreatic enzyme phospholipase-A2, and constitutes roughly 80% of the 
total phospholipids of duodenal content in humans63. Work has demonstrated significantly 
increased carotenoid absorption in lysoPC compared to PC, and significantly increased absorption 
in PC compared to non-choline containing PL’s63. Therefore, dual intake of dietary lutein and 
varying types of choline will promote maximal carotenoid absorption within the small intestine. 
Within the brain, lutein serves as one of several anti-oxidants, and choline (derived from 
the diet or endogenous production) can serve as a precursor for the neurotransmitter ACh48,49. ACh 
has been demonstrated to influence neuronal excitability, alter presynaptic release of 
neurotransmitters, and coordinate the firing of groups of neurons64. In rodent models, high 
acetylcholinesterase (the enzyme that catalyzes breakdown of ACh) activity in the hippocampus 
and cortex has been associated with ethanol-induced memory impairments65. Oral administration 
of lutein was demonstrated to attenuate both acetylcholinesterase activity and ethanol-induced 
memory impairment compared to a control group65. Notably, a limitation of clinical research is the 
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inability to evaluate concentrations of cerebral ACh. It is possible that the benefits derived from 
combined consumption of lutein and choline are due to an increase in cerebral ACh production, 
driven perhaps by lutein’s attenuation of acetylcholinesterase activity and high amount of choline 
intake. 
A single study on the potential interaction between lutein and choline and its subsequent 
effects on cognition has been conducted by Cheatham and et. al.66. Their group examined the 
relationship between choline, docosahexaenoic acid (DHA), and lutein on recognition memory in 
six-month old infants. Nutrient intake was assessed through analysis of breast milk, and 
recognition memory was assessed using a familiar/novel paradigm while infants underwent ERP 
testing. They observed that interactions between choline and DHA, and choline and lutein, were 
significant in predicting latency to peak amplitude in a recognition task while the dietary 
components in isolation were not. This work has yet to be extended beyond of the infant population 
and has not been expanded to cognitive control domains.  
 
While understanding the individual contribution of dietary components to health related 
outcomes has been informative, understanding interactive effects may have increased translation. 
Thus, to expand on research already conducted, complementary nutrition research should focus on 
understanding the impact of interactions between nutrients. The work herein will elucidate the 
individual, as well as interactive, contributions of the dietary components lutein and choline on 






CHAPTER 3: SPECIFIC AIMS AND HYPOTHESES 
The dietary components lutein and choline have been hypothesized to play a protective role 
in cognitive health. Thus, work elucidating their independent and interactive impacts on cognition 
is warranted.  
 
Aim 1 
Aim 1-a: Cross-sectionally examine the role of retinal xanthophyll accumulation on behavioral 
and neuroelectric components of cognitive control in adults with overweight or obesity. 
Hypothesis: Individuals with higher retinal xanthophyll accumulation will exhibit higher 
behavioral performance and neuroelectric patterns, signifying greater neural efficiency. 
 
Aim 1-b: Determine the effect of a 12-week daily Hass avocado randomized controlled trial on 
changes in serum lutein status, retinal xanthophyll concentration, and cognitive control in adults 
with overweight or obesity. 
Hypotheses:  
1. The treatment group receiving a daily meal with an avocado will exhibit increases in 
lutein status (i.e., serum and retina) and improvements in behavioral and neuroelectric 
indices of cognitive control, relative to the control group. 
2. Increases in lutein status will be predictive of improvement in cognitive function. 
 
Aim 2 
Aim 2: Cross-sectionally examine the role of choline intake on behavioral and neuroelectric 
components of cognitive control in adults with overweight or obesity. 
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Hypothesis: Individuals with higher dietary choline intake will exhibit higher behavioral 
performance and neuroelectric patterns signifying greater neural efficiency. 
 
Aim 3 
Aim 3: Cross-sectionally examine the independent and interactive roles of choline and lutein 
intake and choline and lutein status on cognitive control in a sample of adults with overweight and 
obesity. 
Hypotheses:  
1. Individuals with higher dietary intake of lutein and choline will have higher retinal 
xanthophyll accumulation, and higher accumulation of choline metabolites 
(phosphatidylcholine and free choline). 
2. The interactions between dietary intake of lutein and choline, and biomarker  








CHAPTER 4: AIM 1-A: A CROSS-SECTIONAL EXAMINATION OF DIETARY 
AND RETINAL LUTEIN IN ADULTS WITH OVERWEIGHT AND OBESITY1 
 
Abstract 
Scope: Macular accumulation of xanthophyll carotenoids (lutein, zeaxanthin) is known to have 
neuroprotective potential, yet their influence on cognition among adults with overweight and 
obesity remains limited. This study examined the impact of macular xanthophylls on attentional 
resource allocation and information processing speed among adults with BMI ≥ 25 kg/m2.  
Methods and Results: Adults between 25-45 years (N=101) completed heterochromatic flicker 
photometry to determine macular pigment optical density (MPOD). Event-related brain potentials 
were recorded during a visual oddball task. Amplitude and latency of the N2 and P3 indexed 
attentional resource allocation and quantified information processing speed. Covariates included 
age, sex, education, intelligence quotient (IQ), %Fat (DXA) and dietary lutein and zeaxanthin (Diet 
History Questionnaire II). MPOD was inversely related to P3 peak amplitude during the standard 
trials and P3 peak latency during the target trials. Therefore, individuals with higher MPOD 
dedicated fewer attentional resources when attentional demands were low while exhibiting faster 
information processing speed when attentional demands were increased. Further, MPOD was 
inversely related to the N2 mean amplitude during target trials, signifying greater inhibitory 
control.  
Conclusion: These findings are the first to link macular xanthophylls to neuroelectric indices of 
attentional and inhibitory control among adults with overweight and obesity. 
                                                 
1Reprinted with permission from Edwards, C.G., Walk, A.M., Cannavale, C.N., Thompson, S.V., 
Reeser G.E., Holscher, H.D., Khan, N.A. Macular Xanthophylls and Event-Related Brain 
Potentials among Overweight Adults and Those with Obesity. Mol. Nutr. Food Res. 2019, 63. © 




Dietary quality amongst adults is continuously falling short of national recommendations67. 
Concurrent with a failure to meet recommendations, the prevalence of overweight and obesity in 
the United States continues to rise68. This is concerning, as diet quality is an essential component 
of both physical and mental health. Poor diet quality coupled with overweight and obesity is 
associated with a number of co-morbidities, including but not limited to: type 2 diabetes, 
cardiovascular disease, and cognitive decline. Recent work has indicated that diet, even after 
accounting for pertinent body composition and demographic variables, has an increasingly 
relevant role in cognitive health 69. Thus, further investigation of the interactions between diet and 
cognition amongst individuals with overweight and obesity is warranted. 
A group of dietary components identified as carotenoids, in particular the xanthophylls 
lutein and zeaxanthin, have been demonstrated to be pertinent to cognitive health 30,70. Lutein, a 
non-polar, lipophilic molecule, is most commonly found in plants – primarily fruits and vegetables, 
as well as egg yolks 22. Zeaxanthin is derived from similar food items, and thus lutein and 
zeaxanthin quantification from foods is often aggregated across these xanthophylls. Importantly, 
lutein is able to cross the blood-brain barrier, and is the predominant carotenoid in the human brain, 
and has been shown to comprise nearly 77% of infant brain carotenoid concentrations 20. 
Zeaxanthin can similarly cross the blood-brain barrier, yet has been shown to accumulate in 
smaller quantities 21. Conveniently, lutein also accumulates in the macula of the eye alongside 
zeaxanthin and its retinal isomer, meso-zeaxanthin 21. Thus, xanthophyll status can be assessed 
through self-report measures of dietary intake, while Macular Pigment Optical Density (MPOD), 
or retinal accumulation, can be assessed using the validated and non-invasive measure of 
heterochromatic flicker photometry. MPOD levels are closely correlated to xanthophyll 
19 
 
concentrations found in pediatric and geriatric human retina and brain samples, substantiating their 
status as biomarkers of retinal and neural tissue xanthophyll accumulation20,21. 
Preliminary research has indicated that higher accumulation of neural lutein – as assessed 
through retinal MPOD levels – is associated with cognition across the lifespan – with studies in 
childhood, young-to-middle adulthood, and older adulthood27–30. While mechanistic explanations 
for these relationships are thus far sparse, theories point towards lutein’s role in increased neural 
processing speed and improved efficiency of attentional resource facilitation31. Post-receptorally, 
lutein and zeaxanthin are hypothesized to play various neuroprotective roles across the life-span, 
primarily as antioxidants and anti-inflammatory agents. The brain has a high oxygen demand, and 
is comprised of a large number of polyunsaturated fatty acids, thus making it particularly 
susceptible to oxidative damage. While the exact mechanisms of xanthophylls cognitive benefits 
is yet to be understood, it is theorized that the main role of retinal accumulation of xanthophylls is 
antioxidant, and anti-inflammatory32–34. As levels in the retina and the brain have been 
demonstrated to be related, a likely theory is that xanthophylls in the brain play a role similar to 
their role in the retina, though theories related to xanthophylls role in epigenetics and plasticity 
have been proposed. Additional support for xanthophylls role in inflammation draws from work 
in individuals with cardiovascular disease, and reports that xanthophyll status is inversely related 
with circulating inflammatory markers such as c-reactive protein and interleukin 635,36. As 
decrements in cognition have been linked with increased oxidative damage and inflammation, it is 
likely that lutein has a neuroprotective role in this context37.  
Consumption of lutein and zeaxanthin at all stages of life is important, with particular 
importance for individuals who may already be at risk for disruptions in cognitive function, such 
as individuals with overweight and obesity71. Defined as having a body mass index (BMI; kg/m2) 
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greater than 25.0, individuals with overweight and obesity are at higher risk of exhibiting deficits 
in cognition, particularly cognitive control, than their healthy weight peers2. Intriguingly, these 
deficits in cognitive function amongst individuals with overweight and obesity have been observed 
independently of obesity’s clinical consequences such as type 2 diabetes, alterations in glycemic 
control, and metabolic risk factors4. Thus, the introduction of lutein and zeaxanthin into diet may 
serve as a relatively cost-effective approach to preventing, or delaying, cognitive impairments due 
to increased adiposity. An inverse relationship has been proposed between BMI and whole body 
percent fat (%Fat) and MPOD levels, though both study sample populations as well as results 
shown have been inconsistent72–74. The present study is the first to attempt to examine this 
relationship in a sample comprised of solely individuals with overweight or obesity. Regardless, 
the growing population of individuals with overweight or obesity may exhibit benefit from 
increased lutein and zeaxanthin intake similar to their healthy weight peers. 
The present study aimed to elucidate the relationship between macular xanthophylls and 
cognitive control in a population of young-to-middle aged adults with overweight and obesity. To 
assess cognition, event-related potentials (ERPs) were extracted from electroencephalographic 
recordings during a two-stimulus visual Oddball task. Cognitive control is a set of interrelated, yet 
dissociable, set of executive functions that form the foundation for higher-order behaviors such as 
goal-planning, reasoning, and delay of gratification75. Attentional and inhibitory abilities, in 
particular, are vital as they allow for attention to relevant environmental stimuli and inhibition to 
irrelevant stimuli. ERPs are the gold standard for evaluating temporal resolution in response to 
visual stimuli76. Thus, ERPs allow for examination of behavioral measures (i.e. accuracy and 
reaction time) as well the neuroelectric underpinnings that induce behaviors and allow for 
elucidation of the theories proposing a role for lutein in processing speed and efficiency. 
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Specifically, within the Oddball task, we investigated the N2 (N200) and P3 (P300, P3b) 
components. The N2 is a negative-going component occurring roughly 200-300 ms post-stimulus 
onset. The P3 is a positive-going component occurring roughly 300-700 ms post-stimulus onset. 
Longer latencies of the N2 and the P3 in response to visual stimuli have been positively associated 
with cognitive decline, with potential amelioration with positive health behaviors such as a healthy 
diet 10. Previous work has also indicated that adults with overweight and/or obesity exhibit poorer 
performance during attentional and inhibitory control tasks4. However, the extent to which macular 
xanthophylls may provide neuroprotective effects – as assessed by ERPs – among adults with 
elevated weight status has not been directly investigated. Our central hypothesis was that 
individuals with higher macular xanthophyll concentrations – as assed via MPOD – would exhibit 
neuroelectric patterns signifying greater neural efficiency as indicated by faster ERP component 




Adults between 25-45 years of age with a BMI > 25.0 kg/m2 (N=101, mean = 32.78 ± 5.46) 
were recruited from the East-Central region of Illinois using university e-mails and flyers posted 
in community buildings frequented by the public. All subjects provided written informed consent 
prior to study participation. All procedures were administered in accordance with the Declaration 
of Helsinki and were approved by the Ethics Committee of the University of Illinois. Participant 
exclusion criteria included BMI < 25 kg/m2, pregnancy, history of neurological disease, history of 





Anthropometrics and Adiposity 
 Height and weight measurements were completed to calculate BMI using the formula: 
weight [kg]/height [meters2]. Measurements were conducted in triplicate while wearing 
lightweight clothing and no shoes, and the average was used for BMI calculation. A stadiometer 
(model 240; SECA, Hamburg, Germany) and a digital scale (WB-300 Plus; Tanita, Tokyo, Japan) 
were used to measure height and weight, respectively.  
Adipose tissue, specifically, %Fat, was measured by dual energy x-ray absorptiometry 
(DXA) using a Hologic Horizon W bone densitometer (APEX Software version 5.6.0.5; Hologic, 
Bedford, MA). %Fat was computed using the standard Hologic software, as previously 
described77. 
 
Dietary Lutein and Zeaxanthin Assessment 
Habitual dietary consumption of lutein and zeaxanthin were quantified using the National 
Cancer Institute’s (NCI) Diet History Questionnaire II with portion sizes78. The Diet History 
Questionnaire II is a self-report food-frequency questionnaire consisting of 142 items. Data were 
analyzed using National Cancer Institute’s Diet*Calc (Diet*Calc Analysis Program, Version 
1.5.0.) software to quantify nutrient values. The primary variable of interest for the present study 
was the aggregate composite measure of lutein and zeaxanthin. 
 
Intellectual Ability Assessment  
The Kaufman Brief Intelligence Test, Second Edition (KBIT-2) was used to assess 
intelligence quotient (IQ). The KBIT-2 has been nationally normed for ages 4 – 90 to assess 
general intellectual abilities and has been shown to have comparable scores to other intelligence 
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scales79,80. The KBIT-2 is comprised of three subtests. The verbal knowledge subtest includes 60 
questions where the participant responds by choosing which image is most associated with the 
word or question spoken by the researcher. The riddle subtest consists of 48 riddles that have a 
single word response. The matrices subtest has 46 logic problems where the participant must 
choose which of 6 pictures is most associated with a single stimulus picture or which picture best 
completes a 2x2, 2x3, or 3x3 matrix. A summative IQ score is generated by combining the score 
of all three subtests, and normalizing for participant age. 
 
Macular Pigment Optical Density  
MPOD was assessed via a customized hetero-flicker photometry (cHFP) technique 
administered using a macular densitometer (Macular Metrics Corporation, Rehoboth, MA, USA). 
The principles of this technique have been previously described. Briefly, the assessment was 
performed by trained members of the research staff. Participants were asked to view stimuli 
peaking at a measuring wavelength of 460 nm that flickers in counter phase with a 570 nm 
reference (flicker rate being optimized for the optimal width of the subject’s null zone). 
Participants were asked to adjust the radiance to identify a null flicker zone by indicating when 
they could no longer detect the flicker. The task is conducted while the stimulus is centrally-fixated 
(measuring macular pigmentation where it is most dense) and at 7 degrees in the para-fovea (where 
density is minimal). The MPOD score, with standard deviation, is calculated by subtracting the 






Attention and Neuroelectric Function 
Cognitive control was assessed using a two-stimulus visual oddball task. During this task, 
participants viewed a series of large and small white circles on a black background presented 
serially with large circles (5.5 cm diameter) or smaller circles (3 cm diameter, Figure 4.1). The 
larger circles served as the “target” stimulus and were presented during 20% of the trials in a 
random order. The smaller circles served as the “standard” stimulus and were presented during the 
remaining 80% of trials. Participants were instructed using scripted and standardized language to 
respond to the target trials with a right button press. Additionally, participants were positioned at 
a standardized distance away from the stimuli presentation screen. Participants were presented 
with a practice block of 30 trials followed by 200 experimental trials. Stimuli were presented for 
100 ms with a 1000 ms response window and an inter-trial interval of 2000 ms. This task has been 
described in detail previously81. 
 
 
Figure 4.1. Task stimuli and parameters for the Oddball task. Participants viewed a series 
of large and small circles presented serially with large “target” circles (5.5 cm diameter) or 
small “standard” circles (3 cm diameter). Participants completed a practice block of 30 
trials followed by 200 experimental trials. 
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During completion of the oddball task, electro-encephalographic (EEG) activity was 
recorded via a Neuro-scan Quik-cap with 64 scalp electrodes arranged in the international 10-10 
system. A midline sensor placed between Cz and CPz served as a reference and AFz served as the 
ground. Using a Neuroscan Synamps2 amplifier, continuous EEG signal was digitized at a 
sampling rate of 500 Hz, amplified 500 times to 70-Hz filter with a direct current and a 60-Hz 
notch filter. Electro-oculographic (EOG) activity was recorded with a set of four electrodes placed 
at the outer canthus of each eye and above and below the left orbit.   
 
Offline, continuous data were re-referenced to the average mastoids. An independent 
components analysis (ICA) was used to systematically reject eye-blink artifacts from the data. 
Data were submitted to a 0.1 Hz high-pass filter before being submitted to the ICA. If a component 
identified during the ICA was correlated at or above 0.35 with the vertical EOG channel, it was 
considered an eye-blink and subsequently rejected. A time window of -200 to 1200 ms around 
stimulus onset was used for creating stimulus-locked epochs with a -200 to stimulus onset used 
for baseline correction. A 30-Hz zero phase shift low-pass filter was employed. ERP analysis was 
limited to trials with correct responses.  Epochs were excluded if the moving window peak-to-peak 
amplitude exceeded ±100 μV using a 100 ms window and a 50 ms window step. ERP variables of 
interest were the N2 and P3 mean amplitude, peak amplitude, and peak latency. Mean amplitude 
refers to the average amplitude over a given time period (stated per component below) and peak 
amplitude refers to the crest of the waveform during a given time period. Electrode locations were 
determined following post-hoc analysis of maximal voltage localization. The N2 was maximal at 
FZ, and was defined as the average and localized amplitudes and corresponding latency 200-
350ms post-stimulus onset (Figure 4.2). The P3 was maximal over a 6-sensor region of interest 
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(ROI) comprised of C1, CZ, C2, CPZ, CP1, and CP2, and was defined as the localized peak and 
corresponding latency occurring between 350-750 ms after stimulus onset (Figure 4.3).  
 
Statistical Analyses 
 Data were examined for normality using the Shapiro-Wilk test. Given the non-normalized 
distribution of cognitive task measures, non-parametric approaches were utilized to examine 
interrelationships between MPOD and cognitive task performance while adjusting for potentially 
confounding variables. First, variables thought to be predictive of MPOD and cognitive function 
including age, sex, socioeconomic status, education level, %Fat, IQ, and dietary lutein and 
zeaxanthin were initially subjected to Spearman’s Rho (ρ) bivariate correlations. Subsequently, 
variables found to be associated with either the cognitive task measures (i.e., behavioral 
performance, P3 amplitude and latency) or MPOD were adjusted for using partial correlational 
analyses. Further, for illustration purposes, participant cognitive task performance was assessed 
across the lowest and highest quartile scores for MPOD. All analyses were conducted using SPSS 





Participant descriptive characteristics and task performance are summarized in Tables 4.1 
and 4.2. Participants ranged in age from 25 to 45 years (Mean 34.98 ± 5.85 years). Females 
comprised the larger proportion of the study sample (70%) and the vast majority of the sample 
completed had completed a college degree (84%). Sixty one percent of the participants had 
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obesity (i.e., BMI ≥ 30 kg/m2) whereas 39% were of overweight status (i.e., BMI 25 to 29.9 
kg/m2). Approximately 63% of the participants reported consuming less than 2000 µg/day of 

































Mean ± SD 
Age 34.98 ± 5.85 
Sex (F, M) 70, 31 
Education Level 
 
No College Degree, n (%) 16 (16) 
Undergraduate College Degree, n (%) 37 (36) 
Post Graduate Degree, n (%) 48 (48) 
BMI 32.78 ± 5.46 
Overweight, n (%) 39 (39) 
Obese, n (%) 62 (61) 
%Fat 39.4 ± 8.1 
IQ 
MPOD  
107.9 ± 12.4 
0.48 ± 0.26 
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ROI, region of interest 
 
Bivariate Correlations 
Bivariate correlations are summarized in Table 4.3.  Sex (females coded as 0 and males 
coded as 1) was inversely related to %Fat (ρ=-0.74, P<0.01) and positively related to accuracy 
during the target trials (ρ=0.20, P=0.04). Dietary lutein and zeaxanthin was positively related to 
accuracy during the standard trials (ρ=0.20, P=0.05) and MPOD (ρ=0.22, P=0.03). MPOD was 
inversely related to the N2 mean amplitude during the target trials (ρ =0.-0.21, P=0.04) and P3 
peak latency during the Target trials (ρ=-0.28, P<0.01).  Finally , there were no significant 
associations between age, %Fat, IQ, and MPOD and cognitive outcomes of interest (all P’s > 0.07). 
 
Partial Correlations 
 Subsequent partial correlations were conducted to determine the relationship between 
MPOD and cognitive outcomes following adjustment of potential covariates observed to influence 
 
Mean ± SD 
Standard Accuracy, % 91.20 ± 11.22 
Target Accuracy, % 87.53 ± 10.23 
Target Reaction Time, ms 491.15 ± 62.18 
Standard P3 ROI Peak Amplitude, µV 6.32 ± 5.03 
Standard P3 ROI Mean Amplitude, µV 3.87 ± 4.42 
Standard P3 ROI Peak Latency, ms 572.40 ± 119.92 
Target P3 ROI Peak Amplitude, µV 12.70 ± 6.07 
Target P3 ROI Mean Amplitude, µV 8.84 ± 5.64 
Target P3 ROI Peak Latency, ms 562.77 ± 110.77 
Standard N2 Peak Amplitude, µV 3.50 ± 3.88 
Standard N2 Mean Amplitude, µV -1.27 ± 3.84 
Standard N2 Peak Latency, ms 260.97 ± 37.38 
Target N2 Peak Amplitude, µV 2.99 ± 4.50 
Target N2 Mean Amplitude, µV 0.27 ± 4.58 
Target N2 Peak Latency, ms 261 ± 37.0 
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either MPOD or cognitive outcomes based on the initial bivariate correlations (i.e., sex and dietary 
lutein and zeaxanthin). These covariates were applied to the N2 and P3 analyses. In regard to the 
N2, the relationship for mean amplitude in the target trials remained significant (ρ=-0.21, P=0.04). 
In regard to the P3, following adjustment for sex and dietary lutein and zeaxanthin, the negative 
association between MPOD and P3 peak amplitude during the standard trials persisted (ρ =-0.22, 
P=0.03).  Similarly, the inverse association observed between MPOD and P3 peak latency during 
the target trials persisted, even after adjusting for covarites (ρ=-0.27, P<0.01). Therefore, 
individuals with higher MPOD exhibited faster neural processing speed during the target trials. 
Trends were observed between MPOD and P3 mean amplitude during the standard trials (ρ=-0.18, 
P=0.07) as well as the N2 peak amplitude (ρ=-0.18, P=0.08). Grand average ERP waveforms 
comparing the lowest and highest quartile of MPOD values are illustrated in Figure 4.2 and 4.3.  
Discussion 
A converging body of work implicates excess adiposity as a contributing factor to poorer 
cognitive function across the lifespan2,4. However, the identification of dietary factors with the 
potential to provide neuroprotection among populations with elevated weight status has been 
limited. The present study is the first to examine relationships between macular xanthophyll 
accumulation and neuroelectric indices of attention and inhibition among in a sample comprised 
of only adults with overweight or obesity. Following adjustment for pertinent demographic and 
body composition variables, we observed statistically significant relationships between both the 
N2 and P3 ERP components in regard to amplitude and P3 latency. Given that no associations 
between MPOD and cognitive control were observed at the behavioral level (i.e., accuracy and 
reaction time), these findings provide support for the potential benefits of higher macular 
xanthophyll status for neural efficiency during cognitive task performance. 
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Table 4.3. Spearman’s Bivariate Correlations Between Subject Characteristics, Macular Carotenoids, and Attention 
*P<0.05 
**P<0.01 
L + Z, dietary lutein and zeaxanthin; ROI, region of interest
 
Age Sex Education IQ %Fat L + Z MPOD 
Age - - - - - - - 
Sex -0.06 - - - - - - 
Education -0.02 0.05 - - - - - 
IQ -0.06 0.17 0.24* - - - - 
%Fat 0.08 -0.74** -0.17 -0.23* - - - 
L + Z -0.02 -0.05 0.09 0.03 0.02 - - 
MPOD -0.07 0.06 0.19 0.18 -0.07 0.22* - 
Standard Accuracy -0.08 0.02 0.13 0.16 -0.10 0.20* 0.16 
Target Accuracy 0.08 0.20* 0.08 0.12 -0.18 0.04 0.02 
Target Reaction Time -0.01 -0.09 0.08 0.07 -0.10 0.08 0.10 
Standard P3 ROI Peak Amplitude 0.00 -0.03 0.02 -0.02 0.14 -0.04 -0.22* 
Standard P3 ROI Mean Amplitude 0.00 -0.17 0.00 -0.19 0.16 -0.11 -0.07 
Standard P3 ROI Peak Latency -0.05 -0.04 -0.15 0.06 0.12 -0.03 -0.19 
Target P3 ROI Peak Amplitude -0.09 -0.07 0.01 0.05 0.14 0.10 -0.06 
Target P3 ROI Mean Amplitude 0.01 -0.07 -0.04 -0.05 0.12 -0.09 -0.28** 
Target P3 ROI Peak Latency -0.11 -0.06 0.04 0.06 0.16 0.13 -0.03 
Standard N2 Peak Amplitude 0.19 -0.12 -0.14 -0.11 0.19 -0.07 -0.15 
Standard N2 Mean Amplitude 0.18 -0.04 -0.13 -0.10 0.16 -0.08 -0.16 
Standard N2 Peak Latency -0.10 -0.07 0.01 0.04 -0.03 -0.10 0.01 
Target N2 Peak Amplitude 0.18 -0.07 -0.07 -0.14 .214* -0.03 -0.18 
Target N2 Mean Amplitude 0.13 -0.05 -0.02 -0.11 0.19 -0.01 -.210* 















Figure 4.2. Waveform representations of the N2 Standard and Target Trials at electrode site FZ 
among the highest and lowest quartiles of MPOD scores, and representation of the maximal 
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Figure 4.3. Waveform representations of the P3 Standard and Target Trials in a region of 
interest (ROI; 6 electrode sites - C1, CZ, C2, CPZ, CP1, and CP2) among the highest and lowest 
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A growing body of work supports the theory that higher neural lutein concentrations, 
assessed through MPOD, play a role in increased neural processing speed and efficiency of 
attentional resource facilitation. These results, as well as other findings from our research 
laboratory, support these claims of neural efficiency27. Many of the recent findings surrounding 
lutein and neuroefficiency are rooted in studies utilizing the fMRI technique to assess efficiency 
using blood-oxygen-level-dependent (BOLD) signaling. Colleagues Lindergh et. al. and Mewborn 
et. al. have demonstrated efficiency in the spatial dimension, noting increased efficiency in older 
adults in tasks of both verbal learning and visual-spatial processing, respectively82,83. Relying on 
the BOLD signal allows for unmatched spatial resolution, and provides invaluable information on 
the regions of the brain recruited to complete a task. Yet, one limitation of fMRI is its lack of 
temporal resolution.  Our current findings build on these, by demonstrating neural efficiency in 
the temporal dimension amongst individuals with overweight and obesity.  
 
We observed lower mean (N2) and peak (P3) amplitudes with higher MPOD levels, as well 
as faster latency (P3) in an two-stimulus visual Oddball task. This task, in comparison to its 
auditory counterpart, relies on improved visual processing. Retinal xanthophyll accumulation has 
been shown to be related to lutein accumulation in samples of the visual cortex in older adults, and 
has been shown to improve components of visual processing such as contrast sensitivity, self-
report measures of visual fatigue, and potentially even neuronal signaling efficiency in the eye20,84–
86. It is thus possible that improved visual processing underlies the efficiency relationships 
observed here – with initial efficient processing of visual stimuli we can see increased downstream 
efficiency of higher-order tasks. Important to note is the difference in size of the target and standard 
stimuli. While the same color scheme was used across trials (white stimuli on a black background) 
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it is possible that the larger, target circles, indeed require the use of higher amounts of MP and thus 
would be more easily, and perhaps more efficiently, identified in individuals with higher MPOD 
levels. Mean and peak amplitude of the N2 and P3 components reflect the amount of resources 
required for inhibition and categorization of stimuli, respectively. Mean amplitude refers to the 
average amplitude between two periods of time, while the peak amplitude refers to the highest 
point of the component waveform. It is generally interpreted that with higher observed P3 mean 
or peak amplitudes there is increased recruitment of neural resources. In the present study, we 
observed decreased neuroelectric activity amongst adults with higher MPOD levels, yet no 
relationship with behavioral responses. Thus, we can infer that individuals with higher xanthophyll 
accumulation are able to process stimuli more efficiently, i.e., using less resources, than their lower 
MPOD peers. A relationship between the latency of the P3 and higher MPOD levels was also 
observed, further indicating a role for MPOD in efficiency of processing speed. These results are 
important, as cognitive inefficiency, or the need for recruitment of excess resources, has been 
theorized to be a catalyst for cognitive decline87. Often treatment for cognitive decline is not sought 
until overt behavioral differences are observed. These results highlight a role of lutein consumption 
in promoting neural efficiency across the life-span, and in adults with overweight and obesity.  
 
Mechanistic explanations for observed neuroefficiency in both the spatial and temporal 
realm are currently lacking. Our sample was comprised of individuals with overweight and obesity 
who are at a heightened risk factor for increased systemic as well as neuro-inflammation88. 
Systemic inflammation has also been associated with cognitive dysfunction, independently of 
obesity, indicating a pertinent role in the cognitive deficits associated with obesity71. Xanthophyll 
carotenoids, owing to their molecular structures and membrane localization, can serve as efficient 
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antioxidants in a variety of metabolic pathways89. Increased fruit and vegetable intake, and 
subsequent increased xanthophyll carotenoid intake, has been shown to modulate inflammatory 
and oxidative stress pathways and reduce the risk of developing several co-morbidities associated 
with obesity such as type 2 diabetes, atherosclerosis, and cancer90. MPOD levels have been 
previously shown to be inversely related to both BMI and %Fat, increasing the urgency in 
investigating the relationship between MPOD and cognitive control in this growing population. 
Intriguingly, this relationship was not observed in the current study. However, previous work has 
shown that relationships between obesity and MPOD are relatively small in magnitude 73,91. 
Further, it is possible that inclusion of adults with healthy weight status would have increased the 
likelihood of observing relationships between obesity and MPOD. This may also explain the lack 
of association between adiposity measures and cognitive function in the present study. 
Nevertheless, an important implication of the current work is that macular xanthophylls are 
predictive of neural markers of cognitive function and these effects may supersede those of fat 
mass, highlighting the importance of these understudied dietary factors for cognitive benefit. 
 Although the present work is the first to investigate the neuroelectric relationships between 
lutein and zeaxanthin and cognitive control amongst adults with overweight and obesity, it was 
not without limitations. This study was cross-sectional in nature, therefore, relationships observed 
cannot be used to determine directionality or causality. Further studies should investigate lutein 
and zeaxanthin supplementation to determine whether neural efficiency can be increased following 
xanthophyll consumption. This study was also conducted solely amongst adults with overweight 
and obesity, and lacked a healthy weight comparator sample. Finally, our results relied on self-
report dietary intake data as well as MPOD in lieu or serum xanthophyll assessment. Future studies 
examining diet and MPOD in conjunction with biomarker data are thus warranted. 
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The aforementioned limitations notwithstanding, among a sample of young-to-middle aged 
adults, we demonstrated that macular xanthophylls were associated with mean and peak amplitude 
(N2, P3) and latency (P3) of neuroelectric indices underlying human behavior during a cognitive 
task, indicating a role of neural lutein accumulation in neural efficiency amongst adults with 
overweight and obesity. Therefore, these findings have relevance for public health given that 
consumption of fruits and dark green leafy vegetables – rich food sources of xanthophylls – 
consistently falls below recommended guidelines. Future experimental research is needed to 
elucidate vital questions regarding the importance of dose and duration of xanthophyll intake 
necessary for long-term benefit for neurocognitive health among at-risk populations such as those 
with overweight and obesity. 
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CHAPTER 5: AIM 1-B: A RANDOMIZED CONTROLLED TRIAL EXAMINATION 
OF DIETARY, SERUM, AND RETINAL LUTEIN IN ADULTS WITH 
OVERWEIGHT AND OBESITY2 
Abstract 
 
Objectives: Excess adiposity increases risk for cognitive impairment. Consumption of avocado, a 
highly bioavailable source of the xanthophyll lutein, has been shown to improve retinal lutein 
accumulation and cognitive function. Thus, we evaluated the influence of avocado consumption 
on cognitive function and lutein status among adults with overweight and obesity using a 
randomized-controlled with matching design for pertinent study outcomes.  
Methods: A cohort of 84 adults (25-45 years, 31 males) were randomized to a treatment group 
(N=47) that received a 12-week daily meal with fresh Hass avocado or a control group (N=37) that 
received an isocaloric meal (clinicaltrials.gov, NCT02740439). Serum lutein and macular pigment 
optical density (MPOD) were used to assess xanthophyll status. Attention and inhibition were 
assessed using the Flanker, Oddball and Nogo tasks with accompanying electroencephalographic 
(EEG) recording.  
Results: Participants in the treatment group exhibited improvements in serum lutein and accuracy 
in the Flanker task. However, there were no relationships between performance and changes in 
lutein status, nor neuroelectric variables. No significant changes in MPOD were observed.  
Conclusion: Daily avocado intake over 12 weeks, after controlling for covariates, improved 
attentional inhibition and increased serum lutein concentrations among adults with overweight and 
                                                 
2Reprinted with permission from Edwards, C.G., Walk, A.M., Thompson, S.V., Reeser, G.E., 
Erdman, J.W. Jr., Burd, N.A., Holscher, H.D., Khan, N.A. Effects of 12-week avocado 
consumption on cognitive function among adults with overweight and obesity. Int. J. 
Psychophysiol. 2020, 148. © IJP. All rights reserved. 
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obesity. However, the cognitive benefits were independent of changes in lutein concentrations. 
Additional work is necessary to determine non-carotenoid, or carotenoid interactive, dependent 
mechanisms by which avocados may influence cognitive function. 
 
Common abbreviations: Body Mass Index (BMI), Macular Pigment Optical Density (MPOD), 
mono-unsaturated fatty acid (MUFA), poly-unsaturated fatty acid (PUFA), high-performance 




A group of oxygenated plant pigments known as xanthophylls have been demonstrated to 
be pertinent to cognitive health across the lifespan 30,70. Specifically, previous work has focused 
on lutein, a non-polar, lipophilic carotenoid, that is most commonly found in green leafy 
vegetables, fruits, such as avocados, and eggs 22. Zeaxanthin, lutein’s structural isomer, is derived 
from similar food items in significantly smaller quantities, and thus lutein and zeaxanthin 
quantification from foods is generally aggregated. Lutein and zeaxanthin cross the blood-brain 
barrier to preferentially accumulate within the brain and the macula of the eye. Lutein is the 
predominant carotenoid in the human brain, having been shown to comprise 66-77% of total brain 
carotenoid concentrations 20. Lutein’s specific mechanism of action within the brain is still 
undetermined, yet theories point towards lutein’s role as an anti-oxidant and anti-inflammatory 
agent, as well as a contributor to preservation of brain plasticity and efficient gap-juncture 
connectivity 33. While the exact mechanisms by which these xanthophylls impart cognitive benefits 
is yet to be understood, it is known that retinal accumulation of these xanthophylls plays a role in 
blue light filtration, as well as acting as antioxidant and anti-inflammatory agents involved in 
protecting retinal tissue 92.  
Accumulation of lutein, zeaxanthin, and the intermediate meso-zeaxanthin within the 
macula is referred to as macular pigmentation, and levels of macular pigmentation have been 
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reported to be closely correlated to xanthophyll concentrations found in deceased pediatric and 
geriatric brain samples 21. Heterochromatic flicker photometry can be used to non-invasively 
estimate retinal xanthophyll accumulation, referred to as Macular Pigment Optical Density 
(MPOD), thereby serving as a biomarker for neural xanthophylls 20. 
 
Improvements in MPOD, following avocado consumption, have been associated with 
improvements in cognitive function 93. Approximately 90% of avocado carotenoids are the 
xanthophylls lutein, zeaxanthin (quantitatively combined), and cryptoxanthin. One half of a 
medium avocado (60g of edible portion) has been reported by the United States Department of 
Agriculture to contain from 185µg of the combined lutein and zeaxanthin up to 800-1110µg, 
depending on the time of harvest 94. According to the Institute of Medicine, average daily lutein 
and zeaxanthin consumption for adults ages 19 to 30 was 2,032 µg/day 95. Thus, the addition of 
one avocado daily could greatly enhance current lutein and zeaxanthin intake among the general 
population.  The avocado provides an ideal food matrix for lutein and zeaxanthin bioavailability, 
as carotenoids and xanthophylls are more bioavailable when consumed in the presence of fat, and 
when consumed in food sources rather than obtained through supplementation 16. It has been 
hypothesized that carotenoids remain within the enterocyte of the small intestine until long-chain 
fatty acids are available to package and transport the carotenoids through the lymphatic system. 
Avocados are thus a prime food ingredient for facilitating chylomicron formation and lutein 
transportation throughout the body. Due to the high presence of mono- and poly- unsaturated fatty 
acids (MUFAs, PUFAs; 6.6g and 1.24g per 60 g edible fruit, respectively) research has shown that 
carotenoid absorption from green leafy vegetables and salsa is enhanced with the addition of 
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avocado 96. Therefore, if increased consumption of lutein and zeaxanthin may benefit cognitive 
health, the avocado is an ideal method of dietary delivery.  
 
While cognitive health is of global concern, individuals with overweight and obesity are at 
a greater risk for cognitive impairment 2 . Defined as a Body Mass Index (BMI) ≥ 25.0 kg/m2, 
approximately 70% of Americans suffer from overweight or obesity. Numerous studies have 
linked mid-life obesity to later cognitive decline in the areas of intellectual functioning, 
psychomotor performance and speed, visual construction, concept formation, set shifting, and 
decision making, independent of obesity related physical comorbidities 4. Previous work has also 
indicated that adults with overweight and/or obesity exhibit poorer performance during attentional 
and inhibitory control tasks 2. Exact mechanisms of the influence of overweight and obesity on 
cognitive health have yet to be fully elucidated, but several theories have been proposed, including 
but not limited to, increased systemic and neural inflammation, alterations in communication 
between reward centers and control centers of the brain, and alterations in metabolic activity within 
brain cortices 97–99. Previously, lutein and zeaxanthin intake has been cross-sectionally associated 
with beneficial cognitive patterns amongst individuals with overweight and obesity 100. However, 
to our knowledge, intervention trials have not been undertaken to determine causality of these 
relationships. As elevated weight status has been associated with decrements in cognitive 
performance among populations with and without obesity-related comorbidities 71,101, this 
population may benefit from increased lutein intake, facilitated by avocado consumption. 
 
In addition to examination of the impact of obesity on behavioral and self-report measures 
of cognitive health, it is important to examine the underlying neural mechanisms associated with 
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cognition. Assessment of executive function, or cognitive control, in individuals with overweight 
and obesity is important, as this population is at increased risk for cognitive deficits 2. Cognitive 
control processes allow for the formation of intentional and goal-directed behavior. Cognitive 
control can be indexed through behavioral measures (i.e. accuracy and reaction time [RT]) or 
neuroelectric measurement of event-related potentials (ERPs). ERPs refer to a subset of 
electroencephalographic activity that occurs in response to, or in preparation for, a stimulus or 
action 102. Evaluating ERPs in conjunction with behavioral measures allows for assessment of both 
the behavior induced in the cognitive task, as well as the potential neurocognitive underpinnings 
of said behavior. While ERPs have been related to obesity, there has also been research showing 
a potential role for amelioration of obesity-related cognitive deficits with beneficial dietary 
changes 71,103. Thus, individuals with overweight and obesity may disproportionately benefit from 
the addition of food items rich in lutein to their diet. 
 
The primary aim of the present study was to determine the impact of 12-week daily 
consumption of fresh Hass avocado on behavioral and neurolectric indices of cognitive control 
among persons with overweight and obesity. Additionally, we conducted secondary analyses to 
explore whether the cognitive benefits derived from daily avocado consumption were dependent 
on changes in circulating (i.e., serum) and retinal (i.e. MPOD) lutein concentrations. Our central 
hypothesis was that, relative to the control group, participants in the avocado treatment group 
would exhibit greater gains in behavioral performance and neurolectric function during cognitive 
control tasks. Further, our secondary hypothesis was that changes in lutein status would correlate 







The Persea Americana for Total Health (PATH) Study was a 12-week randomized control 
trial conducted in central Illinois (clinicaltrials.gov, NCT02740439) between 2016 and 2018 with 
the primary aims of assessing the impact of 12-week daily Hass avocado on measures of central 
adiposity and glycemic control. Randomization was completed by an algorithm designed by a 
member of the research team who was not involved in data collection (ADMC). Participants were 
assigned to groups using a pseudo-randomization procedure whereby they were matched on 
characteristics theorized to affect cognition including biological sex, age, and weight status, and 
then placed into the treatment or control groups using a random number table. The research team 
and coordinators were blinded to group allocation. Participants randomized to the treatment group 
consumed one meal a day with a Hass avocado, while participants randomized to the control group 
consumed an isocaloric meal matched for macronutrient composition without an avocado. As 
outlined in Table 5.1, the lutein/zeaxanthin content was 3 times higher in the intervention meals 
as it was in the control meals. Owing to the macronutrient composition of avocados, the treatment 
meals were also higher in total fiber (~4-fold) and lower in saturated fats and higher in 
monounsaturated fatty acids. Examples of study meals can be found in supplementary text. The 
study meals were provided on a 7-day menu cycle designed to be similar to a typical American 
diet, and meet the Acceptable Macronutrient Distribution Ranges (AMDR) set by the Institute of 
Medicine (45% carbohydrates, 40% fat, 15% protein). Calories per meal were based on the Harris 
Benedict equation, accounting for a sedentary level of activity 104. Female participants received 
20% less of each item than the male participants. Meals were instructed to be consumed at any 
time during the day. Meal compilation occurred in a metabolic kitchen and each ingredient was 
weighed to the nearest gram. Participants completed meal consumption records and traveled to the 
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test site twice weekly to pick up study meals. Insulated meal coolers, ice packs, and information 












Table 5.1. Nutrient and food group comparison between study meals. 
Nutrient Control Treatment 




Avocado, g Female: 0 
Male: 0 
Female: 140 
Male: 175  
Total Fat, % 39 40 
     SFA, % 17 7 
     MUFA, % 10 24 
     PUFA, % 9 5 
Carbohydrate, % 45 45 
Protein, % 16 14 

























































Compliance was assessed via weekly consumption records, which accounted for the 
percentage of the entire meal consumed, and the percentage of the avocado consumed among 
individuals in the intervention. Per protocol analyses was conducted among individuals who met 
the minimum compliance threshold of 80%.  
 


























n = 81 
Contacted 
n = 821 
Phone Screened 
n = 420 
Not eligible/declined n = 198 
No response n = 203 
Excluded n = 168 
Declined participation n = 74 
 
Randomized 
n = 163 
Avocado Group 
n = 82 
Week 12 follow-up 
n = 37 
Week 12 follow-up 
n = 47 
Lost to follow-up n = 12 
Excluded n = 23 
No blood draw n = 9 
Compliance n = 13 
EEG data n = 1 
Lost to follow-up n = 9 
Excluded n = 35 
No blood draw n = 16 
Compliance n = 16 




Adults between 25-45 years of age with a BMI ≥ 25.0 kg/m2 (N=163) were recruited from 
the East-Central region of Illinois using university e-mails and flyers posted in community 
buildings and buses frequented by the public. All subjects provided written informed consent prior 
to study participation. All procedures were administered in accordance with the Declaration of 
Helsinki and were approved by the Ethics Committee of the University of Illinois. Participant 
exclusion criteria included BMI < 25 kg/m2, pregnancy or lactation, history of neurological 
disease, history of chronic metabolic diseases, non-normal or uncorrected vision based on the 
minimal 20/20 standard, and food allergies or intolerances. Prior to testing, participants completed 
a health history and demographics questionnaire to confirm inclusion criteria and provide further 
health and demographic information. Based on this questionnaire, the highest level of education 
achieved was calculated from an 8-point scale, with 1 indicating less than 7th grade, and 8 
indicating a doctoral degree or equivalent. Full baseline demographic information can be found in 
Table 5.2. Individuals were excluded from analyses if they were lost to follow-up (n=21), did not 
consume ≥ 80% of study meals (29), were unable to complete the study blood draw (25), or did 
not provide useable EEG data (4). Data from one individual in the avocado group was lost to an 





Table 5.2. Descriptive summary of PATH study participant characteristics at baseline and post-testing. 
  Pre-Testing Post-Testing 
Variable Control Group Avocado Group Control Group Avocado Group 
  Mean (SD) Range Mean Range 
Mean 
(SD) Range Mean Range 
N 37   47           
Sex 18F, 16M   23F, 15M           
Age, years 34.0 (6.2) 25.0-45.0 34.6 (5.7) 25.0-45.0         
Intelligence 
Quotient 
109.2 (11.5) 86.0-140.0 110.9 
(12.6) 
89.0-133.0         
Consumption, % 
0.96 (0.05) 82.0-100.0 0.94 
(0.05) 
82.0-100.0         
Highest 
Education, % 
                
High School 20.6   8.0           
College 44.1   26.3           















































²BMI = Body Mass Index     
* Difference between pre- and post-testing is significant at the 0.05 level (2-tailed) 
** Difference between pre- and post-testing is significant at the 0.01 level (2-tailed) 
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Anthropometrics and Adiposity 
 Height and weight measurements were completed to calculate BMI using the formula: 
weight [kg]/height [meters2]. Measurements were conducted in triplicate while wearing 
lightweight clothing and no shoes, and the average was used for BMI calculation. A stadiometer 
(model 240; SECA, Hamburg, Germany) and a digital scale (WB-300 Plus; Tanita, Tokyo, Japan) 
were used to measure height and weight, respectively.  
 
Intellectual Ability Assessment  
The Kaufman Brief Intelligence Test, Second Edition (KBIT-2) was used to assess 
intelligence quotient (IQ). The KBIT-2 has been nationally normed for ages 4 – 90 years to assess 
general intellectual abilities and has been shown to have comparable scores to other intelligence 
scales 79,80. The KBIT-2 is comprised of verbal knowledge, matrices, and riddles subtests. A 
summative IQ score is generated by combining the score of all three subtests, and normalizing for 
participant age. 
 
Serum Carotenoid Assessment 
Serum lutein was assessed using high-performance liquid chromatography (HPLC) as 
previously described 105.  Briefly, 250 µL of serum were mixed with an equal volume of ethanol 
containing 0.1% of butylated hydroxytoluene and vortexed. Serum carotenoids were extracted 
using 3 consecutive, 1 ml hexane extraction processes. Hexane layers were combined, dried under 
nitrogen, taken up into 90% MTBE, 8% methanol, and 2% ammonium acetate in water solution 
(1.5% solution) and then analyzed, in duplicate, for carotenoid concentrations using the Alliance 
HPLC system (e2695 Separation Module) equipped with 2998 photodiode array detector (Waters, 
Milford, MA, USA) and a reverse-phase C30 column (4.6 × 150 nm, 3 micron, YMC, Wilmington, 
NC, USA). Carotenoid standards were obtained from Carotenature (Ostermundigen, Switzerland). 
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For quantification, standard curves were run for each carotenoid, and serum carotenoid 
concentrations were quantified by use of a 2550 ethanol extinction coefficient in a 1% solution. 
 
Macular Pigment Optical Density  
 
MPOD was assessed via a customized hetero-flicker photometry technique administered 
using a macular densitometer (Macular Metrics Corporation, Rehoboth, MA, USA). The principles 
of this technique have been previously described [28]. Briefly, the assessment was performed by 
trained members of the research staff. The same eye was utilized for both pre and post testing 
assessments. Participants were asked to view stimuli peaking at a measuring wavelength of 460 
nm that flickers in counter phase with a 570 nm reference (flicker rate being optimized for the 
optimal width of the subject’s null zone). The operator adjusted the radiance of the stimuli and 
participants were asked to identify a null flicker zone by informing the operator when they could 
no longer detect the flicker. The task is conducted while the stimulus is centrally-fixated 
(measuring macular pigmentation where it is most dense) and at 7 degrees in the para-fovea (where 
density is minimal). The MPOD score, with standard deviation, is calculated by subtracting the 
foveal from the parafoveal log sensitivity measurements after normalization at 570 nm. 
 
Flanker Task 
Attentional inhibition was assessed using a modified Eriksen Flanker task as previously 
described 106. The task order was fixed, with the Flanker task was presented first, followed by the 
Oddball, and then Nogo tasks. Responses were recorded on a 4-button response pad (Current 
Designs, Philadelphia, PA, USA). Briefly, participants viewed a series of 3-cm tall white arrows 
on a black computer screen in front of them. Using standardized and scripted language, participants 
were instructed to respond using a response pad to the direction of a centrally presented stimulus 
(arrow) amongst 4 flanking (2 arrows on each side of the central/target arrow), or distractor, 
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arrows. In the congruent trials, the flanking arrows face the same direction as the central arrow 
(>>>>>), while in the incongruent trials the arrows surrounding the central stimuli are flanked by 
arrows facing the opposite direction (>><>>). The task began with 40 practice trials followed by 
two blocks of 100 randomized, and equiprobable, experimental trials. Stimuli were presented for 
83 ms with a 1000 ms response window and jittered intertrial intervals of 1100, 1300, and 1500 
ms. Behavioral measures of interest included mean accuracy and RT for overall, congruent, and 
incongruent trials.  
 
Oddball Task 
Response inhibition was assessed using a two-stimulus visual Oddball task 100. During the 
Oddball task, participants viewed a mixture of large (5.5 cm diameter) or smaller white circles (3 
cm diameter) on a black computer screen. The larger circles served as the “target” stimulus and 
were presented during 20% of the trials in a random order. The smaller circles served as the 
“standard” stimulus and were presented during the remaining 80% of trials. Participants were 
instructed using scripted and standardized language to respond to the target trials with a right 
button press. Participants were presented with a practice block of 30 trials followed by 200 
experimental trials. Stimuli were presented for 100 ms with a 1000 ms response window and an 
inter-trial interval of 2000 ms. 
 
Nogo Task 
During the Nogo condition participants were asked to respond to the frequent, small circle 
stimuli as targets, requiring them to inhibit responses to the established pre-potent response.  
Participants completed 30 practice “Nogo” trials followed by 200 experimental trials. Stimuli were 
presented for 100 ms with a 1000 ms response window and an inter-trial interval of 2000 ms. 
Measures of accuracy and RT for go and Nogo conditions were assessed. 
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Event-related Potential Assessment 
EEG activity was recorded via a Neuro-scan Quik-cap with 64 passive, wet, sintered 
Ag/AgCl scalp electrodes arranged in the international 10-10 system 107. Electrooculographic 
activity was recorded with a set of four electrodes placed at the outer canthus of each eye and 
above and below the left orbit. A midline sensor placed between Cz and CPz served as a reference 
and AFz served as the ground. Online, using a Neuroscan SynampsRT amplifier, continuous EEG 
signal was digitized at a sampling rate of 500 Hz, amplified 500 times to an online low-pass 70-
Hz filter with a direct current and a 60-Hz notch filter. Impedance values for all electrodes were 
maintained ≤10 kohms. 
Signal processing and analysis were performed in Matlab (Mathworks, Natick, MA, 
version 2017b) using the EEGLab and ERPlab toolbox plug-ins 108,109. Offline EEG pre-processing 
was as follows: continuous data were re-referenced to the average of two mastoid electrodes. Next, 
all channels were plotted and underwent visual inspection for excessive noise by a trained member 
of the research staff. Channels shown to contain excessive noise after visual inspection were 
interpolated with an average of the nearest surrounding electrodes. An independent component 
analysis (ICA) was next used to systematically reject eye-blink artifacts from the data. Data were 
submitted to a 0.1 Hz high-pass butterworth filter before being submitted to the ICA. ICA and 
vertical eye sensor channel correlations greater than 0.35 were considered eye-blinks and were 
thus rejected. A time window of -200 to 1200 ms around stimulus onset was used for creating 
stimulus-locked epochs with a -200 to stimulus onset used for baseline correction. A 30-Hz (24 
dB/octave) zero phase shift low-pass filter was employed. Artifacts were identified and rejected if 
a moving window peak-to-peak amplitude exceeded 100 µV, using a 100-ms window width, and 
100-ms window step. Only correct trials from individuals who reported >50% of artifact-free trials 
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in all Flanker task trials and Target trials of the Oddball and Nogo task were included in analyses, 
as is consistent with previous literature in the field of ERPs and wellness 10,12. 
Electrodes of interest were chosen based on a collapsed localizer technique. Evidence for 
selection was observed from maximal voltage localization of combined baseline and post-testing 
trials collapsed across task conditions. Post-hoc topographic average plots were constructed using 
a stylized topographic map plugin for EEGLAB/ERPLAB 110. Electrodes were consistent across 
tasks. From these topoplots. The N2 was maximal at FCZ, and was defined as the average and 
localized peak amplitudes and corresponding latency 150-300ms post-stimulus onset. The P3 
component was defined as a region of interest comprised of C1, CZ, C2, CPZ, CP1, and CP2 with 
localized peak and corresponding latency occurring between 300-600ms post-stimulus onset. 
 
Statistical Analyses 
All analyses were conducted in SPSS (IBM SPSS Statistics version 24). Per protocol 
analyses were performed among all participants that reported ≥ 80% meal consumption. Intent to 
treat analyses can be found in supplementary material. Given that previously published research 
on avocado consumption effects on neuroelectric measures of cognitive control are lacking, an a 
priori power calculation using a moderate effect size (r=0.25), 2-sided α of 0.05, and 80% power, 
estimated that a sample size of 37 participants/group would be sufficient to address these study 
aims. All statistical analyses were conducted using a two-tailed family-wise alpha threshold of 
0.05. Data were checked for normality using graphical methods (Q-Q plots) and the Shapiro-Wilk 
test. Initial Pearson product-moment correlation analyses were conducted between demographic 
variables as well as measures of adiposity and cognitive outcomes. Those found to be correlated 
with cognitive outcomes at baseline – sex (females coded as 0, males coded as 1), age, IQ, highest 
level of education, and BMI – were included as covariates in subsequent analyses. Analyses of 
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mean accuracy and mean RT were analyzed using unadjusted and adjusted repeated measures 
analyses of variance (ANOVAs/ANCOVAs). Behavioral analyses were modeled as 2 (group: 
control, treatment) x 2 (time: pre, post) x 2 (trial type i.e., congruent vs. incongruent or target vs. 
non-target). ERP and lutein status analyses were modeled as 2 (group) x 2 (time), and 2 (group) x 
2 (time) x 2 (trial type) respectively. Any significant interaction effects observed were 
subsequently analyzed using paired t-tests and adjusted for multiple comparisons using Bonferroni 
correction.  
Following initial modeling, changes in serum lutein concentrations, changes in MPOD, 
and changes in cognitive outcomes were correlated using Pearson product-moment correlations to 
determine associations between changes in lutein status and cognitive variables. 
 
Results 
Compliance and Weight Status 
Self-reported dietary compliance for both groups was high, with overall compliance at 
89.5%. After removal of individuals reporting consumption below 80%, Compliance values were 
95% overall, with 94% reported compliance for the avocado treatment group, and 96% for the 
control group. There were no changes in BMI between pre- and post-testing in the control (p=0.3) 
nor treatment (p=0.8) group. 
Markers of lutein concentrations 
 Unadjusted models for serum lutein concentrations revealed a main effect of time 
(F(1,82)=20.27, p<0.001,p²=0.20), no main effect of group (F(1,82)=0.39, p=0.54,p²=0.005), 
and an interaction effect of time x group (F(1,82)=28.40, p<0.001, p²=0.26). Following 
adjustment for sex, BMI, and age, there was no main effect of time (F(1,79)=0.25, 
p=0.62,p²=0.003) nor group (F(1,79)=0.87, p=0.35,p²=0.01) on serum lutein concentrations; 
however, there was a significant time x group interaction (F(1,79)=26.98, p<0.001, p²=0.26), 
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indicating that the avocado treatment increased serum lutein concentrations (change: 0.04 µmol/L, 
p=<0.001; 95% CI: 0.02 to 0.05;) compared to the control (p=0.3; Figure 5.2) in both the 











 Unadjusted models for MPOD revealed no main effect of time (F(1,82)=2.45, 
p=0.12,p²=0.03), group (F(1,82)=0.05, p=0.83,p²=0.001), nor interaction effect of time x group 
(F(1,82)=0.01, p=0.94,p²=0.00). After controlling for sex, BMI, and age, there was no main 
effect of time (F(1,79)=0.03, p=0.87,p²=0.00), group (F(1,79)=0.05, p=0.83,p²=0.001), nor 
interaction effect of time x group (F(1,79)=0.02, p=0.90,p²=0.00) on MPOD, indicating that 
neither the avocado nor the control group exhibited changes in MPOD over the course of the 12-



























Figure 5.2. Bar graphs of the pre and post testing values and standard error values 
(n=84) for serum lutein concentrations, highlighting statistically significant 
changes in the avocado group (change: 0.04µmol/L, p=<0.001) compared to the 














 At baseline, serum lutein concentrations and MPOD were correlated (r=0.41, p<0.001), yet 
the change in serum lutein concentrations and the change in MPOD throughout the study were not 
correlated (r=0.09, p=0.5). The baseline MPOD and change in MPOD were correlated (r=-0.38, 
p=0.001), indicating that those with higher MPOD at baseline displayed smaller MPOD changes 
throughout the study period. Baseline serum lutein concentrations and the change in serum lutein 
concentrations were not correlated (r=0.08, p=0.9). 
 
Flanker Behavioral Performance 
Full pre- and post-testing data, as well as the number of ERP trials used in each task are 
outlined in Table 5.3. Unadjusted models for accuracy revealed no main effect of time 
(F(1,82)=0.97, p=0.33,p²=0.12) nor group (F(1,82)=2.96, p=0.09,p²=0.04). However, we 















Figure 5.3. Bar graphs of the pre and post testing values for MPOD and standard 
error values (n=84) for MPOD, highlighting no group differences in values across 





effect of time x group (F(1,82)=7.01, p=0.01, p²=0.08). Adjusted models for accuracy revealed 
no main effect of time (F(1,77)=1.17, p=0.28,p²=0.02), group (F(1,77)=2.36, p=0.13,p²=0.03), 
nor congruency (F(1,77)=1.97, p=0.16,p²=0.03), and a significant interaction effect of time x 
group (F(1,77)=8.29, p=0.005, p²=0.10), indicating that individuals in the treatment group 
improved in overall task accuracy (change: 2.2%, p=0.01; 95% CI: 0.5 to 3.9), whereas the control 
group did not (p=0.2). Similarly, the treatment group exhibited improvements in both the 
congruent (change: 1.3%, p=0.05; 95% CI: -3.02 to 2.3) and incongruent (change: 3.0%, p<0.01; 
95% CI: 1.1 to 5.0) trial types, relative to the control group (congruent: p=0.10, incongruent: 
p=0.60; Figure 5.4). Unadjusted analyses for RT revealed no main effect of time (F(1,82)=1.78, 
p=0.19,p²=0.02) or group (F(1,82)=0.46, p=0.50,p²=0.006), a main effect of congruency 
(F(1,82)=969.02, p<0.001, p²=0.92), and an interaction effect of time x group (F(1,82)=6.54, 
p=0.01, p²=0.07), indicating that individuals in the control group improved in RT during 
incongruent trials (change: 25.5ms, p=0.003; 95% CI: 9.6 to 41.4) whereas the treatment group 
did not (p=0.80). Adjusted analyses for RT revealed no main effect of time (F(1,77)=0.68, 
p=0.41,p²=0.01), group (F(1,77)=0.43, p=0.52,p²=0.01), congruency (F(1,77)=1.85, 








Flanker Task N2 
The average number of usable trials in the Flanker task were not different between pre-
testing and post-testing, nor between intervention groups. Unadjusted analyses for N2 peak 
amplitude revealed a main effect of time (F(1,82)=19.50, p<0.001, p²=0.19), no main effect of 
group (F(1,82)=0.76, p=0.39,p²=0.01), a main effect of congruency (F(1,82)=4.59, p=0.04, 
p²=0.05), and no interaction effect of time x group (F(1,82)=0.00, p=0.97,p²=0.00). Adjusted 
analyses for N2 peak amplitude revealed no main effect of time (F(1,77)=2.06, p=0.16,p²=0.03), 
group (F(1,77)=1.00, p=0.32,p²=0.01), nor congruency (F(1,77)=1.25, p=0.27,p²=0.02), and no 
interaction effect of time x group (F(1,77)=0.05, p=0.83,p²=0.00). Unadjusted analyses for N2 
peak latency revealed no main effects of time (F(1,82)=0.00, p=0.99,p²=0.00), group 
(F(1,82)=0.00, p=0.96,p²=0.00), nor congruency (F(1,82)=0.18, p=0.68,p²=0.00), and no 
interaction effect of time x group (F(1,82)=0.54, p=0.47,p²=0.01). Adjusted analyses for N2 peak 







































Figure 5.4. Bar graphs of the pre and post testing values and standard error values (n=84) for 
a) congruent and b) incongruent Flanker accuracy. Improvements in accuracy are observed in 
the avocado group in the congruent (p=0.05) and incongruent (p=0.003) trial types, yet not in 




p=0.95,p²=0.00), nor congruency (F(1,77)=1.76, p=0.19,p²=0.02), and no interaction effect of 
time x group (F(1,77)=0.07, p=0.80,p²=0.00). 
 
Flanker Task P3 
Unadjusted analyses for P3 peak amplitude revealed no main effect of time (F(1,82)=2.47, 
p=0.12,p²=0.03) nor group (F(1,82)=0.00, p=0.98,p²=0.00), a main effect of congruency 
(F(1,82)=18.94, p<0.001, p²=0.19), and no interaction effect of time x group (F(1,82)=0.47, 
p=0.50,p²=0.01). Adjusted analyses for P3 peak amplitude revealed no main effect of time 
(F(1,77)=1.81, p=0.18,p²=0.02), group (F(1,77)=0.00, p=0.95,p²=0.00), nor congruency 
(F(1,77)=2.06, p=0.16,p²=0.03), and no interaction effect of time x group (F(1,77)=0.88, 
p=0.35,p²=0.01). Unadjusted analyses for P3 peak latency revealed a main effect of time 
(F(1,82)=9.90, p<0.001, p²=0.11), no main effect of group (F(1,82)=0.04, p=0.84,p²=0.00), a 
main effect of congruency (F(1,82)=70.20, p<0.001, p²=0.46), and no interaction effect of time x 
group (F(1,82)=0.09, p=0.76,p²=0.00). Adjusted analyses for P3 peak latency revealed a trend-
level main effect of time (F(1,77)=3.71, p=0.06, p²=0.05), no main effect of group (F(1,77)=0.02, 
p=0.90,p²=0.00) or congruency (F(1,77)=2.14, p=0.15,p²=0.03), and no interaction effect of 




Table 5.3. Descriptive summary of PATH study participant characteristics and task performance at baseline. 
  Pre-Testing Post-Testing 
Variable Control Group Avocado Group Control Group Avocado Group 
Flanker Task                 
Overall Accuracy, % 93.5 (4.7) 78.0-98.5 93.4 (5.3) 75.5-99.0 92.5 (5.9) 75.5-100.00 95.6 (3.5)** 80.0-99.5 
Overall RT¹, ms 465.4 (51.1) 369.1-587.6 460.3 (59.4) 360.6-622.0 445.5 (57.3) 320.5-374.2 466.9 (64.1) 374.2-709.9 
Congruent Accuracy, % 97.2 (3.5) 85.0-100.0 96.5 (5.3) 74.0-100.0 95.7 (4.9) 76.0-100.0 97.8 (2.9)* 86.0-100.0 











Incongruent RT, ms 501.7 (51.8) 417.9-626.8 496.0 (59.8) 390.9-641.8 476.2 (58.5) 345.9-588.6 497.8 (63.1) 391.4-711.9 
Usable ERP trials, # 186 (9.5) 155-197 185 (11.2) 150-197 181 (10) 152-200 186 (17.3) 104-198 
Oddball Task                 
Overall Accuracy, % 88.6 (11.19) 56.5-100.0 91.6 (7.7) 55.5-99.5 92.8 (7.6) 62.0-100.0 93.2 (6.0) 69.0-100.0 
Non-Target Accuracy, 
% 
88.9 (14.2) 50.0-100.0 94.1 (9.4) 50.0-100.0 94.3 (9.6) 53.0-100.0 95.5 (7.3) 62.0-100.0 
Target Accuracy, % 87.4 (10.3) 62.5-100.0 81.6 (14.5) 50.0-100.0 87.2 (14.6) 50.0-100.0 83.5 (11.8) 50.0-100.0 
Target RT, ms 491.7 (74.2) 354.5-736.8 506.9 (64.4) 364.0-605.5 518.2 (60.1) 370.6-659.3 534.5 (72.7) 385.4-703.6 
Usable ERP trials, # 176.0 (24.1) 92.0-199.0 180.0 (17.4) 103.0-198.0 182.0 (20.0) 96.0-198.0 174. (17.0) 103.0-199.0 
NoGo Task                 
Overall Accuracy, % 85.7 (8.5) 64.5-98.5 86.5 (10.3) 46.5-99.0 85.9 (13.6) 50.0-98.5 88.5 (8.4) 52.5-98.5 
Non-Target Accuracy, 
% 
90.1 (8.3) 70.1-100.0 90.4 (12.9) 50.0-100.0 89.1 (17.1) 50.0-100.0 92.6 (9.6) 48.8-100.0 
Non-Target RT, ms 457.9 (71.2) 331.9-617.8 442.6 (71.8) 303.1-632.4 446.1 (76.7) 303.4-598.7 445.2 (78.6) 305.4-661.6 
Target Accuracy, % 68.5 (11.2) 50.0-97.5 70.9 (9.2) 50.0-95.0 73.0 (10.8) 50.0-95.0 72.0 (8.9) 50.0-37.5 
Usable ERP trials, # 166.0 (20.4) 90.0-198.0 168.0 (21.4) 91.0-196.0 167.0 (22.0) 93.0-197.0 169.0 (23.4) 94.0-196.0 
¹RT = Reaction Time     
* Difference between pre- and post-testing is significant at the 0.05 level (2-tailed) 
































Oddball Behavioral Performance 
Unadjusted analyses for accuracy revealed a main effect of time (F(1,81)=4.94, p=0.03, 
p²=0.06), no main effect of group (F(1,81)=0.36, p=0.55,p²=0.00), a main effect of trial type 
(F(1,81)=25.30, p<0.01, p²=0.24), and no interaction effect of time x group (F(1,81)=0.27, 
p=0.60,p²=0.00). Adjusted analyses revealed no main effects of time (F(1,76)=0.13, 
p=0.72,p²=0.00), group (F(1,76)=0.23, p=0.63,p²=0.00), nor trial type (F(1,76)=2.37, 
Figure 5.5. Waveform depictions of a lack of significant differences (n=84) between 
post testing values for a Flanker task for the a) N2 and b) P3 ERP components and the c) 
difference waves between control and intervention pre- and post-testing during a 12-
week avocado intervention. Topoplots d) and e) represent the electrode sites of the 
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p=0.13,p²=0.03), and no interaction effect of time x group (F(1,76)=0.99, p=0.32,p²=0.01). 
Unadjusted analyses for RT revealed a main effect of time (F(1,81)=21.13, p<0.001, p²=0.21), no 
main effect of group (F(1,81)=1.25, p=0.27,p²=0.02), a main effect of trial type 
(F(1,81)=45524.93, p<0.001, p²=1.00), and no interaction effect of time x group (F(1,81)=0.00, 
p=0.95,p²=0.00). Adjusted analyses for RT revealed no main effect of time (F(1,76)=1.12, 
p=0.29,p²=0.02) nor group (F(1,76)=1.93, p=0.17,p²=0.03), a main effect of trial type 




Unadjusted analyses for N2 peak amplitude revealed a main effect of time (F(1,81)=44.63, 
p<0.001, p²=0.36), no main effects of group (F(1,81)=1.21, p=0.28,p²=0.02), nor trial type 
(F(1,81)=2.44, p=0.12,p²=0.03), and no interaction effect of time x group (F(1,81)=1.94, 
p=0.17,p²=0.02). Adjusted analyses for N2 peak amplitude revealed no main effect of time 
(F(1,76)=1.14, p=0.29,p²=0.02), group (F(1,76)=0.89, p=0.35,p²=0.01), nor trial type 
(F(1,76)=0.01, p=0.91,p²=0.00), and no interaction effect of time x group (F(1,76)=3.04, 
p=0.09,p²=0.04). Unadjusted analyses for N2 peak latency revealed a main effect of time 
(F(1,81)=8.22, p=0.01, p²=0.09), no main effect of group (F(1,81)=0.02, p=0.89,p²=0.00), a 
main effect of trial type (F(1,81)=11.88, p<0.001, p²=0.13), and an interaction effect of time x 
group (F(1,81)=4.30, p=0.04, p²=0.05). Adjusted analyses for N2 peak latency revealed no main 
effect of time (F(1,76)=0.58, p=0.45,p²=0.01), group (F(1,76)=0.32, p=0.57,p²=0.00), nor trial 
type (F(1,76)=1.41, p=0.24,p²=0.02), and an interaction effect of time x group (F(1,76)=3.95, 
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p=0.05, p²=0.05), indicating that the control group exhibited longer latencies (change: 24.2ms, 
p=0.02; 95% CI: 4.7 to 44.1) at post-testing in the Target trial types. 
 
Oddball P3 
Unadjusted analyses for P3 peak amplitude revealed no main effect of time (F(1,81)=0.30, 
p=0.59,p²=0.00) nor group (F(1,81)=0.05, p=0.82,p²=0.00), a main effect of trial type 
(F(1,81)=118.07, p<0.001, p²=0.60), and no interaction effect of time x group (F(1,81)=0.34, 
p=0.56,p²=0.00). Adjusted analyses for P3 peak amplitude revealed no main effect of time 
(F(1,76)=0.53, p=0.47,p²=0.01), group (F(1,76)=0.23, p=0.63,p²=0.00), nor trial type 
(F(1,76)=0.85, p=0.36,p²=0.01), and no interaction effect of time x group (F(1,76)=0.52, 
p=0.48,p²=0.01). Unadjusted analyses for P3 peak latency revealed no main effect of time 
(F(1,81)=2.31, p=0.13,p²=0.03), group (F(1,81)=0.99, p=0.32,p²=0.01), nor trial type 
(F(1,81)=1.11, p=0.30,p²=0.01), and no interaction effect of time x group (F(1,81)=2.20, 
p=0.14,p²=0.03). Similarly, adjusted analyses for P3 peak latency revealed no main effect of time 
(F(1,76)=2.32, p=0.13,p²=0.03), group (F(1,76)=2.14, p=0.15,p²=0.03), nor trial type 
(F(1,76)=2.05, p=0.16,p²=0.03), and no interaction effect of time x group (F(1,76)=2.87, 


















Nogo Behavioral Performance 
Unadjusted analyses for accuracy revealed no main effect of time (F(1,81)=2.60, 
p=0.11,p²=0.03) nor group (F(1,81)=0.41, p=0.52,p²=0.01), a main effect of trial type 
(F(1,81)=94.76, p<0.001, p²=0.54), and no interaction effect of time x group (F(1,81)=0.00, 
p=0.95,p²=0.00). Adjusted analyses for accuracy revealed no main effects of time (F(1,76)=2.83, 
































































Post - Pre Difference Waves
Figure 5.6. Waveform depictions of lack of significant differences (n=83) between post 
testing values for Oddball Task for the a) N2 and b) P3 ERP components and the c) 
difference waves between control and intervention pre- and post-testing during a 12-
week avocado intervention. Topoplots d) and e) represent the electrode sites of the 
collapsed (by trial, group, and timepoint) representations of the N2 and P3 components. 
a) b) 
c) d) e) 
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p=0.84,p²=0.00), and no interaction effect of time by group (F(1,76)=0.39, p=0.53,p²=0.01). 
Unadjusted analyses for RT revealed no main effect of time (F(1,81)=0.49, p=0.49,p²=0.01) nor 
group (F(1,81)=0.29, p=0.59,p²=0.00), a main effect of trial type (F(1,81)=42554.68, p<0.001, 
p²=1.00), and no interaction effect of time x group (F(1,81)=1.19, p=0.28,p²=0.01). Adjusted 
analyses for RT revealed no main effect of time (F(1,76)=0.07, p=0.79,p²=0.00) nor group 
(F(1,76)=0.04, p=0.84,p²=0.00), a main effect of trial type (F(1,76)=178.10, p<0.001, p²=0.70), 
and no interaction effect of time x group (F(1,76)=0.64, p=0.43,p²=0.01). 
 
Nogo N2 
Unadjusted analyses for N2 peak amplitude revealed a main effect of time (F(1,81)=41.56, 
p<0.001, p²=0.36), no main effects of group (F(1,81)=0.02, p=0.89,p²=0.00), nor trial type 
(F(1,81)=1.69, p=0.20,p²=0.02), and no interaction effect of time x group (F(1,81)=0.14, 
p=0.71,p²=0.00). Adjusted analyses for N2 peak amplitude revealed no main effect of time 
(F(1,76)=0.33, p=0.57,p²=0.01), group (F(1,76)=0.00, p=0.95,p²=0.00), nor trial type 
(F(1,76)=0.05, p=0.83,p²=0.00), and no interaction effect of time x group (F(1,76)=0.05, 
p=0.82,p²=0.00). Unadjusted analyses for N2 peak latency revealed a main effect of time 
(F(1,81)=4.49, p=0.04, p²=0.06), no main effect of group (F(1,81)=0.28, p=0.60,p²=0.00) nor 
trial type (F(1,81)=0.17, p=0.68,p²=0.00), and no interaction effect of time x group 
(F(1,81)=1.19, p=0.28,p²=0.02). Adjusted analyses for N2 peak latency revealed no main effect 
of time (F(1,76)=0.62, p=0.43,p²=0.01), group (F(1,76)=0.19, p=0.66,p²=0.00), nor trial type 






Unadjusted analyses for P3 peak amplitude revealed no main effect of time (F(1,81)=3.37, 
p=0.07,p²=0.04) nor group (F(1,81)=0.09, p=0.76,p²=0.00), a main effect of trial type 
(F(1,81)=6.86, p=0.01, p²=0.08), and no interaction effect of time x group (F(1,81)=0.55, 
p=0.46,p²=0.01). Adjusted analyses for P3 peak amplitude revealed no main effect of time 
(F(1,76)=0.23, p=0.64,p²=0.00), group (F(1,76)=0.00, p=0.98,p²=0.00), nor trial type 
(F(1,76)=0.95, p=0.33,p²=0.01), and no interaction effect of time x group (F(1,76)=0.59, 
p=0.45,p²=0.01). Unadjusted analyses for P3 peak latency revealed no main effect of time 
(F(1,81)=0.14, p=0.71,p²=0.00) nor group (F(1,81)=0.05, p=0.82,p²=0.00), a main effect of 
trial type (F(1,81)=4.49, p=0.04, p²=0.06), and no interaction effect of time x group 
(F(1,81)=0.05, p=0.82,p²=0.00). Adjusted analyses for P3 peak latency revealed no main effect 
of time (F(1,76)=0.83, p=0.37,p²=0.01), group (F(1,76)=0.56, p=0.46,p²=0.01), nor trial type 
(F(1,76)=0.48, p=0.49,p²=0.01), and no interaction effect of time x group (F(1,76)=0.17, 









 Bivariate correlations between change scores (post-testing minus pre-testing values) were 
conducted. There were no relationships between the change in serum lutein, nor change in MPOD, 
and changes in changes in cognition in either the behavioral or the neuroelectric outcomes (all 
p’s>0.2). 
 
Figure 5.7. Waveform depictions of lack of significant differences (n=83) between post 
testing values for the Nogo Task for the a) N2 and b) P3 ERP components and the c) 
difference waves between control and intervention pre- and post-testing during a 12-
week avocado intervention. Topoplots d) and e) represent the electrode sites of the 
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An emerging body of literature indicates that obesity is a risk factor for poorer cognitive 
health among children and adults. Therefore, there is an increasing need for development of 
nutritional interventions with the potential to promote or prevent cognitive decline among persons 
with overweight or obesity 71,98. This 12-week randomized controlled trial investigated the impact 
of daily avocado consumption on measures of cognitive control and lutein status among young-to-
middle-aged adults with overweight and obesity. Consistent with the a priori hypothesis, we 
observed that participants in the avocado treatment group exhibited significantly greater accuracy 
during the Flanker task in both the unadjusted and adjusted models, signifying improvement in 
attentional inhibition. However, there were no significant changes in response inhibition; 
therefore, the cognitive benefits of avocado consumption were domain specific and not 
generalized. Regarding secondary hypotheses pertaining to the role of lutein, we observed that the 
avocado treatment group exhibited a significant improvement in serum lutein status; however, 
there were no significant changes in retinal xanthophyll deposition. Further, the changes in serum 
lutein concentrations or retinal xanthophyll accumulation did not correlate to benefits in cognitive 
task performance. Therefore, the cognitive benefits were evident independent of changes in lutein 
status. These findings demonstrate, for the first time, that 12-week daily avocado consumption 
benefits cognitive control performance among individuals with overweight and obesity. 
 
 The xanthophyll carotenoids lutein and zeaxanthin have recently received considerable 
interest for their neurocognitive potential across the lifespan 111. Previous work has shown that 
supplementation with either lutein or zeaxanthin or a combination of the two xanthophylls can 
significantly improve several behavioral aspects of cognitive function 112,113. However, food-based 
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approaches for enhancing cognitive function have been limited. To the authors knowledge, only 
one previous study has examined the effect of avocado intake on xanthophyll status and cognitive 
function 93. In 2017, Scott and colleagues found that daily avocado intake over 6 months improved 
memory function among older adults 93. The authors were able to link improvements in MPOD 
with changes in cognitive outcomes; thereby, demonstrating a direct association between changes 
in MPOD and cognitive benefits.    
 
Following comprehensive adjustment of covariates including adiposity, intellectual ability, 
and education level, the avocado treatment group exhibited significant improvements in accuracy 
during an attentional inhibition task. Intriguingly, these improvements were not correlated with 
observed changes in serum lutein, and were evident in the absence of changes in MPOD. 
Nonetheless, 12-week daily avocado consumption was associated with improvements in cognitive 
performance amongst an otherwise healthy cohort of young-middle-aged adults with overweight 
or obesity. While these improvements were not related to changes in serum lutein concentrations, 
these changes were only apparent in the avocado-consuming group, suggesting that the 
improvements observed can be attributed to a component of the avocado. These improvements 
were also seen in both the unadjusted and adjusted models, indicating that avocado consumption 
may be associated with cognitive health even after controlling for important pertinent covariates. 
Avocados contain a plethora of beneficial dietary components, nutrients, and phytochemicals, 
including but not limited to unsaturated fatty acids, dietary fiber, folate, vitamin K, and potassium. 
Previous clinical trials have demonstrated that avocado consumption is associated with 
improvements in blood lipid profiles, decreased weight status, and more regular bowel movements 
94. Therefore, avocado consumption may benefit cognitive function via indirect pathways 
68 
 
involving improvements in digestive and metabolic health or direct mechanisms involving 
alterations in neural lipid and inflammatory profiles 114,115. These findings warrant further 
examination of the potential implications of other nutrients found in avocados on cognitive health. 
 
Due to a lack of change in MPOD in the current sample, null results in regards to the 
neuroelectric findings are not entirely surprising. Previously, our laboratory has cross-sectionally 
evaluated MPOD and the N2 and P3 components in these tasks. These results demonstrated a 
relationship between MPOD and mean amplitude of the N2 and peak amplitude of the P3, yet no 
relationships between MPOD and behavioral measures have been previously demonstrated 100. 
Therefore, as changes in MPOD were not observed across the study period, previous findings 
supporting the role of MPOD and processing in the temporal realm are supported. In the Oddball 
task we observed an increased latency of the N2 in the control group, indicating a slowing of 
processing speed that was not observed in the avocado group. Previous work has pointed to the 
detrimental impact of the Western diet on cognitive function, specifically implicating saturated 
fats, as well as low fiber intake 116. It is possible that the addition of avocado to the current diet 
may have prevented this decrement amongst the treatment group. 
 
 Carotenoid status is not only dependent on diet but can also be influenced by various intra-
subject factors including degree of adiposity and genetics 16. Of course, between-person 
differences in lutein bioavailability and metabolism exist, and thus the authors took care to include 
necessary and comprehensive covariates in all analyses. Within this study, we observed a 75% 
increase in serum lutein concentrations amongst the participants in the avocado group, 
substantiating claims that while quantitatively relatively low in lutein concentration (537µg 
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compared to supplementation studies including gram dosages), the avocado fruit matrix is a highly 
bioavailable food source for lutein intake 96. In the 2017 study, Scott et. al. found that the addition 
of 135g of Hass avocado daily for 6-months improved both serum lutein concentrations and 
MPOD, though improvements in MPOD were observed in both the avocado and the control group. 
Increases in MPOD were not related to increased serum lutein concentrations. MPOD 
improvements were observed as early as 3-months in both groups, which is also the duration of 
the currently described trial. Possible explanations for the lack of improvements in MPOD in the 
current sample are three-fold: sample demographics, baseline MPOD levels, as well as the degree 
of MPOD eccentricity evaluated could have all played a role. The sample utilized by Scott and 
colleagues was comprised of older adults (mean age = 63.3 years) of healthy weight status (mean 
BMI = 24.1 kg/m²), whereas the present work included young-to-middle aged adults (mean age = 
34.1 years) with overweight or obesity (mean BMI = 32.0 kg/m²). Differences in nutrient 
absorption, dietary patterns, as well as systemic inflammation could influence the efficacy of lutein 
transport and absorption, as well as the role that lutein plays within the body. Also, study 
participants in the study by Scott and colleagues had a baseline mean MPOD of 0.39, while the 
participants in the present study began the trial with a higher baseline retinal accumulation, with 
an average MPOD of 0.48. Given that the avocado treatment by Scott et al. resulted in an average 
MPOD of 0.49 at 6 months, it is possible that we observed a ceiling effect, where by participants 
in the present study had higher MPOD at enrollment with little room for improvement. It is also 
possible that a longer feeding period or higher avocado dose may be necessary to change MPOD 
status among persons with overweight and obesity. On the other hand, substantial increases in 
serum lutein concentrations were observed in both studies, thus substantiating theories that serum 
lutein serves as a transient biomarker of acute lutein intake. Similarly, it is possible that in this 
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sample of adults with overweight and obesity, and presumably more neural inflammation than a 
healthy weight adults, changes in xanthophyll accumulation in the brain may have occurred prior 
to any observable changes in MPOD. The assessment of MPOD in the present study was solely 
conducted at the central-eccentricity of 0.50o, while lutein is known to linearly increase with 
distance from the fovea 117. While previous work has demonstrated improvements in MPOD at 
this eccentricity with lutein supplementation, it is possible that changes in retinal status, and 
perhaps associated changes in behavioral performance, may have been evident outside of this point 
of reference 118. 
 
A strength of this study included the reliance on a randomized-controlled study design to 
address the primary aims. We also employed, for the first time, the use of behavioral assessment 
in conjunction with the ERP technique to gain insights into the neural or mechanisms by which 
avocados impact brain function. Further, we used lutein biomarkers in serum and retina to test 
whether lutein status changes were necessary to derive cognitive benefits.  However, this study 
was not without limitations. This study solely utilized a sample of individuals with overweight and 
obesity, limiting its translation to healthy weight individuals. Though, given that recent Center for 
Disease Control figures quantify the percentage of Americans with overweight or obesity as nearly 
70% of the population, examining of beneficial effects of diet on cognition in this population is 
warranted and increasingly generalizable 119. This study also utilized a fixed order style of task 
presentation. While it may be argued that the Flanker task preceding the Oddball and Nogo tasks 
may have impacted the subsequent tasks, the stimuli between tasks were different, and practice 
blocks were given between each task. Future studies would also benefit from inclusion of other 
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cognitive tasks and neuroimaging techniques e.g., magnetic resonance imaging to gauge the 
interaction between brain structural and functional changes and avocado intake.  
In conclusion, this study utilized a randomized-control trial to investigate the impact of 12-
week daily avocado consumption on measures of cognitive control and lutein status among a 
sample of individuals with overweight and obesity. We observed that avocado intake significantly 
increased serum lutein status over the control group in models both adjusted and unadjusted for 
pertinent covariates, while no differences were observed in macular pigmentation. The changes in 
serum lutein concentrations were not related to behavioral changes observed in the avocado group, 
and neuroelectric changes were not observed across either group. Future studies are needed to 
investigate the impact of longer-term daily avocado consumption on markers of macular 
pigmentation and cognitive health across the lifespan. Further, considering that the avocado is a 
fruit that is rich in several nutrients with neurocognitive potential e.g., fibers, monounsaturated 
fatty acids, and phytochemicals, additional work examining the influence of other nutrients in the 
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CHAPTER 6: AIM 2: A CROSS-SECTIONAL EXAMINATION OF DIETARY 




Objectives: Converging evidence indicates that obesity is associated with poorer brain health and 
cognitive function. However, it is not clear whether specific dietary factors may provide 
neuroprotective effects among individuals with overweight and obesity. Specifically, the essential 
nutrient choline may play an important neuroprotective role across the lifespan. Thus, it is 
concerning that only 1 in 10 adults meets the recommended intake for dietary choline. Further, 
there is a lack of research examining the impact of habitual choline intake on specific aspects of 
cognitive function among adults with overweight or obesity. Accordingly, the aim of this study 
was to examine the impact of choline intake on neurophysiological markers of attentional control 
among young and middle-aged adults with overweight or obesity. 
 
Methods: 146 adults with BMI ≥ 25kg/m2 (34.0 ± 5.9 years, 57 males) participated in the study. 
Behavioral performance (accuracy and reaction time) and neuroelectric indices (event-related 
brain potentials [ERPs]) of attentional inhibition were assessed during a modified Eriksen Flanker 
task. Specifically, amplitude and latency of the P3 waveform in a central-parietal region of interest 
(ROI) was used to index attentional resource allocation and information processing speed, 
                                                 
3Reprinted with permission from Edwards, C.G., Walk, A.M., Cannavale, C.N., Flemming, I.R., 
Thompson, S.V., Reeser, G.E., Holscher, H.D., Khan, N.A. Dietary choline is related to neural 
efficiency during a selective attention task among middle-aged adults with overweight and 
obesity. Nutr. Neurosci. 2019. © NN. All rights reserved. 
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respectively. Choline intake and overall diet quality (Healthy Eating Index [HEI-2015]) were 
assessed using 7-day diet records. General intellectual ability (IQ) was assessed using the Kaufman 
Brief Intelligence Test. Linear regression analyses were conducted to examine the relationship 
between habitual dietary choline intake and cognitive outcomes following adjustment of 
demographic factors, IQ, HEI-2015, and BMI. 
 
Results: Only 19% of the participants reported meeting their daily recommended intake for 
choline. After controlling for covariates, choline intake was selectively associated with lower peak 
amplitude of the P300 waveform during incongruent task trials (β = -0.25, p=<0.01). No significant 
relationships were observed for accuracy or reaction time.  
 
Discussion: Given that individuals with greater choline intake exhibited lower P3 amplitude to 
achieve similar levels of behavioral performance, these results indicate that higher choline intake 
is associated with more efficient neural processing amongst adults with overweight and obesity, 
even after controlling for pertinent demographic factors, weight status, and overall diet quality. 
Future intervention studies are necessary to determine whether choline consumption provides 
neuroprotective effects for other facets of executive function across the lifespan among individuals 













Diet quality in the United States is continuously falling short of national 
recommendations120. This failure to meet recommendations has been linked to the concurrent rise 
in the prevalence of obesity, with recent reports indicating that 70% of US adults are living with 
overweight or obesity121. While diet is a known contributor to physiological health, it is also a 
pertinent contributor to brain and cognitive health. Better diet quality has been associated with 
improvements in memory, slowed cognitive decline, and even as a potential safeguard against 
Alzheimer’s Disease122. With a perpetual failure to meet current dietary recommendations, as well 
as a continual prevalence of overweight and obesity, further research is warranted to understand 
the impact of nutritional intake on cognition among individuals with overweight and obesity. 
Choline, an essential water-soluble nutrient, has been linked to cognitive improvements 
among perinatal and geriatric populations. Choline is vital for neurotransmitter synthesis (as the 
precursor to acetylcholine [ACh]), cell-membrane integrity (through phosphatidylcholine), and 
methyl-donor metabolism (through the conversion of methionine to homocysteine), and higher 
choline intake has been associated with lower whole body % fat and higher levels of lean 
mass43,123. Choline can also be produced through de novo biosynthesis through the 
phosphatidylethanolamine N-methyltransferase pathway, albeit in concentrations that are 
insufficient to maintain many biological processes40. Thus, it is imperative that choline be 
consumed through diet. Common foods rich in choline include eggs (147 mg/serving), soybeans 
(107 mg/serving), chicken breast (72 mg/serving), and beef (72 mg/serving). The Institute of 
Medicine recommends an Adequate Intake (AI) for choline of 425 mg/d for women and 550 
mg/day for men41. However, 90% of the US population does not meet this AI recommendation41. 
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Choline plays a vital role in central nervous system development and choline 
supplementation has been shown to benefit memory and brain development in human and pre-
clinical models44. Phosphatidylcholine and sphingomyelin, the two most prevalent forms of 
choline in the body, form essential structural components of cell membranes and myelin sheaths 
throughout the brain and the body. Surprisingly, the relation of choline intake to executive function 
has been seldom studied. Executive function, often referred to as cognitive control, is comprised 
of a set of interrelated, yet dissociable, higher order processes including attention (the ability to 
resist distractions and maintain focus), response inhibition (the ability to inhibit responses to 
stimuli), and cognitive flexibility (the ability to dynamically shift attention and alter response 
strategy to changing demands)5. These processes allow for the ability to interact with, as opposed 
to merely respond to, salient stimuli in the surrounding environment. Deficits in cognitive function, 
in particular executive function, have been often used as early markers of cognitive decline124. 
Executive function can be indexed through behavioral measures (i.e. accuracy and reaction time 
[RT]) or the more sensitive neuroelectric measurement of event-related potentials (ERPs). ERPs 
refer to subset of electroencephalographic activity that occurs in response to, or in preparation for, 
a stimulus or response102. Evaluating ERPs in conjunction with behavioral measures allows for 
assessment of both the behavior induced in the cognitive task, as well as the neurocognitive 
underpinnings of said behavior. More specifically, this study investigated the P3 (i.e. P300, P3b), 
a positive-going ERP component that occurs in adults 300-700 ms post-stimulus onset and is 
generated by several neural generators including the prefrontal cortex (PFC)125. The P3 is 
associated with context updating, or revision of the mental representation induced by incoming 
stimuli, as well as attentional resource allocation126. The peak amplitude of the P3 represents the 
amount of neuronal resources required for performing cognitive tasks that elicit higher attentional 
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demands, while the latency represents the speed of stimulus evaluation and classification. Thus, 
tasks that are less cognitively demanding and require fewer attentional resources will elicit smaller 
P3 amplitudes with decreased P3 latencies when compared to their more attention demanding 
counterparts. As elevated weight status has been associated with decrements in cognitive 
performance among populations with and without obesity-related comorbidities71,101, this 
population may benefit from heightened habitual choline intake. 
 
 The PFC is comprised of cholinergic projects, stemming from the basal forebrain, as well 
as cholinergic targets, through ACh receptors44. Thus, dietary choline consumption stands to 
impact the function of, and behaviors derived from, the PFC. This relationship has been 
demonstrated in animal models, as well as in older adult populations, yet there are few studies 
investigating these relationships in younger adults. Therefore, there remains limited data on the 
potential of choline to have neuroprotective effects across the lifespan and among populations with 
overweight and obesity. Accordingly, the aim of this study was to examine the impact of choline 
intake on attentional inhibition, a marker of executive function, in middle-aged adults with 
overweight or obesity. We hypothesized that individuals who consumed higher levels of dietary 
choline would exhibit improved behavioral performance on an attentional inhibition task as 
observed through higher accuracies and faster RTs. Additionally, we hypothesized that individuals 
with higher choline intake would exhibit more efficient neural processing, signified by lower P3 








Cross-sectional data were collected from 167 middle-aged adult participants with 
overweight and obesity (BMI ≥25kg/m2). Recruitment consisted of flyers and university mailings 
resulting in a population of both community and university members. To qualify for the study, 
participants had to provide all demographic data, complete the Kaufman-Brief Intelligence Test 
(KBIT-2), provide a readable electroencephalographic (EEG) recording, record their dietary intake 
for at least 7 days using a diet record, and be free of diagnosed neurological disorders and diseases 
(including ADD/ADHD and autism). All participants provided verbal and written informed 
consent in accordance with the University of Illinois’ Institutional Review board and the 
Declaration of Helsinki. After excluding participants who (a) had less than 7-days of recorded diet 
record entry (8), (b) were outliers in behavioral or dietary measures (10) (± 3 SD), or (c) had 
excessive noise in their EEG signal (3) , we obtained 146 (34.04 ± 5.91 years, 57 male) participants 




Participant testing was completed over two laboratory visits. On the first visit, informed 
consent was obtained, followed by administration of the KBIT-2, and height and weight 
assessments for Body Mass Index (BMI) calculation. On the second visit to the laboratory, 
participants completed cognitive testing. All ERP testing was conducted in the morning hours 
(between 6:00 am and 9:30 am) in the fasted state to avoid the confounding effects of acute 
macronutrient consumption on cognitive outcomes127. Participants were instructed at their Day 1 
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appointment as well as in an e-mail reminder to arrive to the laboratory for cognitive testing 
following a 10-hour fast of all food and beverage items apart from water. Compliance to this 
protocol was verbally assessed prior to cognitive testing and failure to comply resulted in 
rescheduling of the appointment. Following the cognitive testing, participants were educated on 
dietary record keeping by a staff member and sent home with a 7-day diet record that was returned 
at a later date. 
 
Anthropometric Measures 
To calculate BMI (kg/m2), height and weight were assessed using a stadiometer (model 
240; SECA, Hamburg, Germany) and a digital scale (WB-300 Plus; Tanita, Tokyo, Japan). 
Participant height and weight were assessed while wearing light clothing and no shoes. The 
average of 3 measurements of height and weight were used for analyses. 
 
Habitual Diet Quality 
Diet analyses were conducted using the 2015 Nutrition Data System for Research (NDSR) 
software (Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN, USA). Only 
participants who completed at least 7 days of entry were included for further analyses. Average 
choline intake over the 7-day period was assessed using the averages of the NDSR Intake 
Properties Totals Output File. Healthy Eating Index (HEI-2015) was calculated to assess 
participants’ dietary patterns. HEI, developed as a measure of overall diet quality, scores 
individuals on a scale of 0-100 based on compliance to the recommendations of the 2015 Dietary 
Guidelines for Americans. The HEI contains 13 components, including nine adequacy (minimum 
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standard) and four moderation (maximum allowed) components. The component scores are then 
summed to calculate the total HEI-2015 score128. 
 
Intelligence Quotient 
KBIT-2 is a test of general intellectual abilities that has been nationally normed for ages 4 
– 90 years79. The test is comprised of three subtests: Verbal Knowledge, Riddles, and Matrices. 
The Verbal Knowledge test includes 60 questions where the participant responds by selecting an 
image that is most associated with the word or question spoken by the researcher. The Riddle 
subtest consists of 48 riddles that have a single word answer. The Matrices test has 46 multiple 
choice problems where the participant must choose which of 6 pictures is most associated with the 
single stimulus picture or which picture best completes a 2x2, 2x3, or 3x3 matrix. In each of the 
subtests, correct answers are given a score of 1 and the total scores are converted into standard 
scores which have a maximum of 100.  A composite score of the three subtests is then utilized as 
a measure of general intellectual abilities. 
 
Flanker Task 
Attentional inhibition was assessed using a modified Eriksen Flanker task. Participants 
viewed a series of arrows on a computer screen in front of them. Using standardized and scripted 
language, participants were instructed to respond using a response pad to the direction of a 
centrally presented stimulus (arrow) amongst four flanking, or distractor, arrows. In the congruent 
trials, the flanking arrows face the same direction as the central arrow (>>>>>), while in the 
incongruent trials the arrows surrounding the central stimuli are flanked by arrows facing the 
opposite direction (>><>>). The congruent task trials have been demonstrated to require 
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significantly decreased attentional resources in young to middle aged adult’s samples. The task 
began with 40 practice trials followed by two blocks of 100 randomized, and equiprobable, 
experimental trials. Stimuli were presented for 83 ms with a 1000 ms response window and jittered 
intertrial intervals of 1100, 1300, and 1500. Behavioral measures of interest included mean 
accuracy and RT for both congruent and incongruent trials.  
 
ERP Assessment 
EEG activity was recorded via a Neuro-scan Quik-cap with 64 scalp electrodes arranged 
in the international 10-10 system as previously described. Electrooculographic activity was 
recorded with a set of four electrodes placed at the outer canthus of each eye and above and below 
the left orbit. A midline sensor placed between Cz and CPz served as a reference and AFz served 
as the ground. Using a Neuroscan SynampsRT amplifier, continuous EEG signal was digitized at 
a sampling rate of 500 Hz, amplified 500 times to an online low-pass 70-Hz filter with a direct 
current and a 60-Hz notch filter. Impedance values for all electrodes were maintained ≤ 10 kohms. 
Offline, continuous data were re-referenced to the average mastoids. An independent 
components analysis (ICA) was used to systematically reject eye-blink artifacts from the data. 
Data were submitted to a .1 Hz high-pass filter before being submitted to the ICA. ICA and vertical 
EOG channel correlations greater than .35 were considered eye-blinks and were thus rejected. -
200 to 1200 ms around stimulus onset was used as a time window for creating stimulus-locked 
epochs with a -200 to stimulus onset used for baseline correction. A 30-Hz zero phase shift low-
pass filter was employed.  
Based on evidence observed from post-hoc topographic images, a region of interest (ROI) 
comprised of C1, CZ, C2, CPZ, CP1, and CP2 was utilized for P3 assessment. Topographic grand 
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average plots were constructed using a stylized topographic map plugin for EEGLAB/ERPLAB110. 
Only correct trials from individuals who reported >50 usable trials in both congruent and 
incongruent trial types were used for analyses. Responses were considered valid if they occurred 
within a time window of 0-1200 ms post-stimulus onset. The P3 component was defined as the 
localized peak and corresponding latency occurring between 300-600 ms post-stimulus onset. 
 
Statistical Analysis 
The Statistical Package for the Social Sciences (SPSS, version 24, IBM, Armonk, New 
York) software was used for all statistical analyses. Variables that did not meet normality 
distributions, with p<0.05 as assessed by Shapiro-Wilk, were log transformed. To examine the 
association between choline intake and attentional, inhibition hierarchical linear regression 
analyses were conducted. Step 1 consisted of variables that have been previously shown to be 
related to both choline intake (HEI-2015) as well as cognitive variables (Sex, Age, BMI, and IQ). 
Step 2 consisted of log transformed choline intake. The significance of the change in the R2 value 
between the two steps was used to assess the independent contribution of choline intake for 
explaining variance in cognitive outcomes beyond that of the demographic factors, IQ, BMI, and 
HEI-2015. Significance was set at p<0.05. To depict neuroelectric waveforms and topoplots, and 
solely as a means of visual representation, a median split was conducted to assign participants as 
either “low” or “high” choline consumers. Independent t-tests were conducted to examine 








Participants spanned 25-45 years of age. Participants were adults with overweight (46%) 
or obesity (54%) (mean BMI = 32.49 ± 6.11 kg/m2). Of the 146 participants analyzed, average 
choline intake was 359.53 ± 134.74 mg/day. Only 18% of females, 22% of males, and 19% of our 
overall sample reported consuming choline adequate to meet their recommended AI. Consistent 
with previous findings, males were consuming significantly more choline than females (p<0.01)41. 
There were also differences in IQ (p<0.01) and BMI (p<0.01) between males and females. Total 
participant characteristics are outlined in Table 6.1. 
Table 6.1. Demographic characteristics, weight status, and Flanker performance variables¹ 
  Value 
 Group Female Male 
N 146 89 57 
Age, y 34.04 ± 5.91 34.39 ± 5.78 33.48 ± 6.12 
IQ 109.26 ± 12.68** 107.02 ± 12.24 112.75 ± 12.68 
BMI, kg/m² 32.49 ± 6.11** 33.7 ± 5.69 30.58 ± 6.31 
HEI-2015³ 50.1 ± 12.54 49.83 ± 11.93 50.51 ± 13.53 
Choline, mg 359.53 ± 134.74** 313.27 ± 107.48 431.76 ± 141.93 
Congruent Accuracy, % 96.55 ± 3.45 95.98 ± 4.02 97.44 ± 2.56 
Congruent RT, ms 417.18 ± 51.13 418 ± 47.41 415.91 ± 56.86 
Incongruent Accuracy, % 90.1 ± 6.75 89.41 ± 7.21 91.17 ± 5.86 
Incongruent RT, ms 485.67 ± 52.02 488.24 ± 50.11 481.66 ± 55.07 
¹ Values are means ± SD unless otherwise stated 
² Determined by the Center for Disease Control Body Mass Index (BMI) classifications 
³ Calculated using National Cancer Institute Healthy Index (HEI) 2015 Assessment 
* Significant differences between groups (p > 0.05) 
** Significant differences between groups (p > 0.01) 
 
Behavioral Performance 
Cognitive variables were used as dependent variables, while predictors in Step 1 consisted 
of BMI, Sex, Age, IQ, and HEI-2015, and Step 2 consisted of choline intake. In regard to accuracy, 
Step 1 produced a significant model for congruent and incongruent accuracy (p=0.04; p=0.01), but 
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a significant change in R² was not observed with the addition of choline intake in Step 2 (all 
p’s>0.05). In regard to RT, Step 1 also resulted in a significant model fit for congruent RT 
(p=0.03), but not for incongruent RT (p>0.05). Step 2 did not significantly change the R² for either 
congruent or incongruent trials. Representations of accuracy performance after conduction of a 
median split across low and high levels of choline consumption are depicted in Figure 6.1. 
P3 Amplitude and Latency 
P3 waveform and topographic plots are depicted in Figures 6.2 and 6.3. The average 
number of missing trials per participant was 3, out of 200, trials. Results of hierarchical linear 
regression analyses for all variables are displayed in Table 6.2. In regard to peak amplitude, Step 
1 did not produce a significant model for congruent peak amplitude (p=0.09), but did for 
incongruent peak amplitude (p=<0.01). With the addition of choline intake in Step 2, there was no 
significant change in R² for congruent amplitude (p>0.05), but there was a significant R² change 
for incongruent amplitude (β = -0.25, p=<0.01). In regard to latency, Step 1 did produce a 
significant model (p=<0.01) for congruent latency driven by BMI (β = 0.18, p=0.04) and IQ (β = 
-0.27, p=<0.01). The addition of choline intake in Step 2 did not produce a significant R² change 
(β = -0.02, p=0.82). Neither Step 1 nor Step 2 produced a significant model for incongruent latency 









Table 6.2. Linear Regression between pertinent variables, choline intake, and 
Flanker ERP variables.      
  Congruent Incongruent 
  Amplitude Latency Amplitude Latency 
Step and 
Variable β (SE) ΔR² 
Model 
P β (SE) ΔR² 
Model 
P β (SE) ΔR² 
Model 
P β (SE) ΔR² 
Model 
P 









































Step 2                       
Choline 
Intake 
-0.13 (2.50) 0.01 0.07 -0.02 
(33.99) 
0.00 <0.01 -0.25** 
(2.48) 
0.05** 0.00 0.07 
(32.74) 
0.00 0.63 
SE = Standard Error 
        
**Correlation is significant at the 0.01 level (2-tailed).         





















Figure 6.1. a) Mean (SE) response accuracy and b) P3 peak amplitude for a median split of 
participants into low (248.75 ± 6.31 mg/day) and high (470.32 ± 10.96 mg/day) choline consumers 










































































































Figure 6.2. a) Waveform depictions of a median split of choline consumers into low and high 
choline consumption of the compiled Flanker task trials, and b) a topographic representation of 


























High Choline Consumers 
(470.32 ± 10.96 mg/day) 











Low Choline Consumers 
(248.75 ± 6.31 mg/day) 







Figure 6.3. Topographical distribution plots of the P3 amplitude for congruent and incongruent 

















The aim of the present study was to examine the relationship between choline intake in 
middle-adulthood among individuals with overweight and obesity and attentional inhibition, a 
marker of executive function. No difference in behavioral measures were observed, yet individuals 
with greater choline consumption exhibited lower P3 peak amplitude during an attentional 
inhibition task. Thus, we are able to interpret that individuals with higher dietary choline intake 
were able to exhibit comparable behavioral performance while requiring less attentional resources. 
Interestingly, the positive relationships were only evident for the incongruent task condition, 
pointing to the selective benefits of dietary choline for cognitive processes requiring upregulation 
of attention or greater amounts of attentional inhibition.  
Mechanistically, much is still to be learned about the role of choline in the human neocortex 
throughout the lifespan. Choline, when combined with acetyl coenzyme A via choline 
acetyltransferase, forms the neurotransmitter ACh39. ACh plays an integral role in the regulation 
of cortical activity (including attention) across multiple timescales through its ability to change 
neuronal excitability, alter presynaptic release of neurotransmitters, and coordinate the firing of 
groups of neurons64. The PFC as well as the anterior cingulate cortex, the proposed sites of P3 and 
attention origination, are deeply innervated with cholinergic projections, stemming primarily from 
the basal forebrain. The vital role of ACh on attention has been shown in pre-clinical literature 
with decrements in attention produced through cholinergic lesions and observations of increased 
levels of ACh in the PFC in response to attentionally demanding tasks129,130. These results have 
been demonstrated particularly amongst the higher taxing, and higher attentional resource-
demanding task trials131. Surprisingly few human studies have examined behavior and choline or 




Within the current Flanker task design we presented a randomized mix of minimally (congruent) 
and higher (incongruent) taxing stimuli. While behavioral results were not observed in this study, 
consistent with previous literature, we did observe differential recruitment of attentional resources 
between the two trial types, as indexed by the P3 component. 
This is, to the author’s knowledge, the first study to examine concurrent choline intake 
amongst humans and its association with neuroelectric markers of attention. ERPs are summative 
postsynaptic potentials and are elicited when large numbers of cortical pyramidal neurons fire in 
synchrony when processing stimuli102. The magnitude of elicited voltages can be modulated by 
the presence and absence of neurotransmitters, such as ACh. Our results reveal evidence that 
higher choline consumption impacts the magnitude of the ERP potential, potentially by increasing 
the amount of cerebral ACh through greater available neurotransmitter substrate. The P3, as a 
resolute marker of attentional resource allocation, can be differentially interpreted. Often a higher 
P3 peak amplitude can be observed as improved attentional resource facilitation, while a lower P3 
peak amplitude can be interpreted as an increased neural efficiency. As we observed no differences 
in behavioral performance, we can infer that individuals using fewer resources to reach the same 
level of performance as their lower-consuming peers are thus processing stimuli more efficiently. 
Often, when assessing cognition, decrements are not detected until overt behavioral changes can 
be observed and this is frequently too late for proper treatment. The lack of differences in 
behavioral outcomes observed here highlights the necessity of utilizing behavioral measures in 
conjunction with more sensitive performance characterization techniques, such as the ERP. 
Choline intake also impacts the brain structurally. In the Framingham Offspring Study, 
Poly et. al. reported that middle-aged, healthy individuals (mean age = 60.1 years) with higher 




intake and White Matter Hyperintensity (WMH), an associated marker of cognitive impairment 
and Alzheimer’s Disease46. As white matter integrity has been associated with better performance 
on cognitive variables such as reading, IQ, information-processing, and attention, this again points 
to the neuroprotective role of choline in the neocortex across the lifespan57. Based on our results, 
it is possible that this neuroprotection may be characterized by neural transmission and efficiency. 
Therefore, examining dietary components, such as choline, that may increase neural efficiency, 
may prove to be beneficial for neuroprotection as well as quality of life throughout the lifespan. 
Interestingly, WMH has also been associated with obesity, in particular the metabolically 
active visceral adiposity has been positively associated with the increased presence of WMH58. 
Choline intake has also been associated with lower levels of whole body % fat in middle-aged 
adults43. Thus, our sample of individuals with overweight and obesity is particularly susceptible to 
cognitive benefits from improved diet quality. In this sample, we observed longer latencies on the 
congruent version of the task among individuals with greater weight status (r=0.16, p=0.05), yet 
adiposity did not serve as a contributing variable in the incongruent trial types. Even so, while the 
study of obesity on cognition is not to be discounted, these results highlight the importance of 
studying obesity within the context of diet and other lifestyle factors. 
There has been research conducted within animal models that suggests a role of maternal 
choline intake on cognitive ability throughout the lifespan132. Among animal models, high 
maternal choline intake in-utero has been linked with higher subsequent measures of visuospatial 
memory across the lifespan, perhaps due to the choline’s fundamental contributions to brain 
formation and neural development45,53. In human work, the closest replication of this animal work 
is evidenced through the Project Viva Study. Two iterations of literature have emerged from this 




observed relationships between maternal choline intake and cognitive outcomes, yet at age 7 
higher maternal choline intake was associated with improved visual memory54,55. These studies 
investigated the impact of maternal intake and did not assess choline intake at the time of cognitive 
testing. Therefore it is difficult to determine the potential differential impact of maternal and 
concurrent choline intake in these studies. Maternal intake was not assessed in the present study, 
and it is thus impossible to know whether the effects seen here are driven by early maternal intake, 
or by current choline intake. Nonetheless, there is a current lack of research investigating the role 
of either maternal or concurrent choline in middle adulthood.  
It is important to note that 81% of our participants did not meet AI recommendations for 
choline consumption, with males consuming more than females, findings which align with national 
intake patterns41. Nevertheless, our study was able to highlight differences in P3 amplitude even 
at suboptimal levels of choline intake. Further research is needed to support increasing choline 
consumption amongst this age group for quality of cognitive life and, as our population was of 
childbearing age, for quality of life for future generations.  
This study derived its strengths from its novel use of behavioral assessment in conjunction 
with the ERP technique in relation to dietary choline intake. Of note, this is not common within 
the field of nutritional neuroscience. Interestingly, the beneficial influence of choline intake was 
only evident for the neuroelectric measures, emphasizing the need to utilize both standard 
behavioral outcomes with neurophysiological data when studying dietary choline’s implications 
for cognitive function. Albeit, this study was not without limitations. First, this study was solely 
comprised of a sample of adults with overweight or obesity, limiting its translation to healthy 
weight individuals. Given that recent Center for Disease Control figures quantify the percentage 




of choline intake in this population is warranted and generalizable119. Second, our study was cross-
sectional in nature and, thus, we can only infer associations as opposed to causality. Third, our 
study did not include the use of biomarkers to assess choline status alongside dietary intake. Future 
studies are needed to investigate relationships between choline status and cognitive outcomes. 
Nevertheless, these associations highlight the need for dietary interventions aimed at increasing 
choline intake across the lifespan. 
This study observed positive associations between neural efficiency, as indexed through 
the P3 component, and dietary choline intake amongst individuals with overweight and obesity. 
Further, this work represents, to our knowledge, the first study to link dietary choline intake with 
cognitive outcomes in young to middle-aged adults. As only 1 in 10 adults in the US are currently 
consuming adequate choline, this study highlights a pressing need for future studies aimed at 
further investigating the link between choline intake and executive function, and improving dietary 
choline intake across the lifespan. 
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CHAPTER 7: AIM 3: A CROSS-SECTIONAL EXAMINATION OF INTERACTIONS 
BETWEEN DIETARY CHOLINE INTAKE AND BIOMARKER STATUS OF LUTEIN 




Background: Independent consumption and biomarker status of the xanthophyll carotenoids 
lutein+zeaxanthin and the dietary component choline have been linked to benefits in cognition. 
However, knowledge on the interactive influence of these dietary components on cognitive 
function is sparse.  
 
Objective: We examined cross-sectional associations between dietary intakes and biomarkers of 
lutein+zeaxanthin and choline with cognitive flexibility among adults with overweight and 
obesity. 
 
Design: 80 young-to-middle-aged adults with overweight and obesity (BMI ≥25.0 kg/m²), 
completed 7-day diet records, venous blood draws, heterochromatic flicker photometry for 
assessment of macular pigmentation, the Kaufman Brief Intelligence Test – 2 for assessment of 
intelligence quotient (IQ) and a Switch task of cognitive flexibility while undergoing 
electroencephalographic recording for event-related potential (ERP) extraction. Multiplicative 
interaction terms were calculated to assess interactive capabilities60,61. Hierarchical linear 




utilized to assess independent and interactive contributions of dietary and metabolite data on 
Switch task outcomes. 
Results: Higher intake of lutein+zeaxanthin, and choline was associated interactively, but not 
independently, with faster reaction time (RT), even after controlling for pertinent covariates. 
Dietary intake of lutein+zeaxanthin and choline was associated with serum lutein concentrations, 
but not with plasma choline metabolites nor macular pigmentation. Plasma phosphatidylcholine 
(PC) concentrations were associated with higher accuracy in Switch trials, while no other 
biomarkers were associated with cognitive outcomes. Dietary intake and biomarker data were not 
related to the N2 nor P3 ERP component. 
 
Conclusions: Individuals with greater dietary intake of choline and the xanthophylls 
lutein+zeaxanthin exhibited faster RT during the cognitively demanding trials of a cognitive 
flexibility task. Higher circulating PC was associated with higher response accuracy. The benefits 
derived from interactive consumption and PC on cognitive flexibility were evident without 
differences in the N2 or P3 component, suggesting alternative neural benefits of xanthophyll and 





Recent evidence has supported the beneficial role of nutrition on cognitive health, 
particularly among the 70% of Americans currently suffering from overweight or obesity 3. The 




cognitive health. This approach limits the understanding of the potential interactive capabilities of 
dietary components on cognitive function. Therefore, additional research examining the interactive 
influence of nutrients with potential complementary influences on cognitive function is needed. 
Two dietary components that have been both inversely associated with adiposity and 
related to cognitive health are the xanthophyll carotenoids lutein+zeaxanthin and the nutrient 
choline 43,72,100,106. Lutein is a fat-soluble molecule found primarily in plant pigments 22. In the 
majority of nutrient databases lutein is aggregated with its lesser occurring stereo-isomer, 
zeaxanthin. Therefore, the term lutein will be used throughout to describe aggregated 
lutein+zeaxanthin intake. Lutein accumulates preferentially within the eye and the brain in related 
increments allowing for a non-invasive assessment of cortical lutein accumulation through the 
measurement of macular pigment optical density (MPOD) 19,133. Choline is a nutrient found 
primarily in fish, poultry, and egg yolks and is involved in neurotransmitter synthesis (as the 
precursor to acetylcholine [ACh]), cell-membrane integrity, and signaling function (through 
phosphatidylcholine [PC]) 39,41,42. Both lutein and choline are diet-dependent – carotenoids are not 
synthesized de novo, and while humans are capable of de novo choline synthesis, it is not 
synthesized in sufficient amounts 123. Approximately 90% of the US population does not meet the 
recommended adequate intake for choline (425 mg/d for women and 550 mg/day for men) 41. 
While there are no dietary reference intakes for lutein consumption, average adult consumption is 
approximately 1-2 mg/day, with efficacious benefits suggested at 6 mg/day 95,134.  Lutein and 
choline have exhibited interactive roles in absorption and circulation; in vitro as well as in vivo 
work has demonstrated that carotenoid absorption is enhanced with not only co-consumption of 




Independently, both lutein and choline intake have been related to beneficial cognitive 
control, or the processes that allow humans to engage in higher-order functioning including 
reasoning, problem-solving, and planning 75. Cognitive flexibility is perhaps the most demanding 
component of cognitive control. Cognitive flexibility builds upon lower-facets of cognition, 
namely inhibitory control and working memory, to allow for flexibility, spontaneity, and adaption 
to our ever-changing environments. Cognitive flexibility is frequently assessed using tasks 
designed to assess behavioral outcomes such as accuracy and reaction time (RT), and these 
behavioral outcomes have been shown to benefit from aerobic activity and diet in human 
populations, as well as choline supplementation in rodent models 6–8. While these behavioral 
benefits have been observed, further explanation of underlying inducting mechanisms of these 
benefits are less understood. Utilizing electroencephalographic recording of potentials time-locked 
to task stimuli (event-related potentials [ERPs]) allows for exploration of the neural mechanisms 
of mental chronometry potentially responsible for observed behavioral differences. Specifically, 
potentials emitted at the level of the scalp (ERP’s) can be used to quantify the magnitude of 
resources required, and speed of processing necessary, for cognitive processes. The N200 (N2), a 
negative-going potential occurring approximately 200ms post-stimulus onset is an index of 
response inhibition, while the P300 (P3, P3b) is a positive-going potential occurring between 300-
700ms post-stimulus onset as an index of context updating, resource allocation, and categorization 
102. Utilizing ERPs in conjunction with behavioral responses to explore the associations of dietary 
intake and status may therefore explicate the dietary derived cognitive benefits previously 
observed in cognitive flexibility tasks. 
While it is assumed that all individuals may cognitively benefit from a healthy diet, 




the interactive influence of lutein and choline on cognition has only once been studied once, and 
not in a sample older than infancy 66. Therefore, this study aimed to examine the associations 
between dietary intake of lutein and choline, biomarker concentrations of serum lutein and MPOD, 
plasma free choline and PC concentrations, and their individual and interactive impacts on 
cognitive flexibility among a sample of middle-aged adults with overweight and obesity. We 
hypothesized that individuals with higher consumption and biomarker concentrations of these 
components would exhibit interactive benefits for cognitive flexibility. 
Methods 
Subjects 
Participant characteristics are described in Table 7.1.  Baseline data from 80 adults enrolled 
in a larger clinical trial (NCT02740439), with body mass indices (BMI) ranging from 25.0 to 57.7 
kg/m² were utilized. To qualify for the study, participants had to have a BMI > 25.0 kg/m², be 
between 25-45 years of age, successfully complete study sample collections, and be free of 
diagnosed neurological disorders. Participants were recruited using flyers posted in community 
settings, e-mails sent to University employees, as well as word-of-mouth recruitment, and were 
compensated with gift cards upon completion of all study procedures. All participants provided 
verbal and written consent in accordance with the University of Illinois’ Institutional Review 
Board and the Declaration of Helsinki. 
Testing Appointments 
During the first laboratory visit, participants provided demographic data including 
household income, completed the Kaufman Brief Intelligence Test II (KBIT), and height and 
weight measurements were recorded for BMI assessment. In between visits one and two, 




second laboratory visit, cognitive testing was conducted following a 10-hour fast in the morning 
hours between 6:00am and 9:00am to reduce the potentially confounding effects of acute meal 
consumption on cognitive performance127. Following cognitive testing a fasted venous blood draw 
was performed for collection of serum and plasma samples for assessment of serum lutein 
concentrations and plasma choline metabolites. 
Anthropometric Measures 
To calculate BMI (kg/m2), height and weight were assessed using a stadiometer (model 
240; SECA, Hamburg, Germany) and a digital scale (WB-300 Plus; Tanita, Tokyo, Japan). 
Participant height and weight were assessed while wearing light clothing and no shoes. The 
average of 3 measurements of height and weight were used for analyses. 
Intelligence Quotient 
KBIT-2 is a test of general intellectual abilities that has been nationally normed for ages 4 
– 90 years 79. The test is comprised of three subtests: Verbal Knowledge, Riddles, and Matrices. 
A composite score of the three subtests is calculated and utilized as a measure of general 
intellectual abilities. 
Serum Carotenoid Assessment 
Serum lutein concerntations were assessed using high-performance liquid chromatography 
(HPLC). This technique has been previously described 105.  Briefly, 250 µL of serum were mixed 
with an equal volume of ethanol and vortexed. Serum carotenoids were extracted using 3 
consecutive, 1 ml hexane extraction processes. Hexane layers were combined, dried under 
nitrogen, taken up into a water solution and then analyzed, in duplicate, for carotenoid 
concentrations using the Alliance HPLC system (e2695 Separation Module) equipped with 2998 




150 nm, 3 micron, YMC, Wilmington, NC, USA). Carotenoid standards were obtained from 
Carotenature (Ostermundigen, Switzerland). Standard curves were run for each carotenoid, and 
serum carotenoid concentrations were quantified by use of a 2550 ethanol extinction coefficient in 
a 1% solution. 
Plasma Choline and Choline Metabolite Assessment 
Phosphatidylcholine (PC) was extracted from 100 µL of plasma and was quantified by 
liquid chromatography–tandem mass spectrometry (LC-MS/MS) according to the method of Koc 
et. al. 136 with modifications based on available instrumentation 137. Free choline was measured by 
LC-MS/MS as previously described 138. Briefly, 100 µL of 0.1% formic acid in acetonitrile and 5 
µL of internal standard mix was added to 50 uL of plasma. Internal standard mix contained choline 
D13 (CDN Isotopes). After vortexing and centrifugation, 5 µL of clear supernatant was injected 
on Syncronis Silica 150 x 2.1, 5u column with matching guard column (ThermoFisher Scientific). 
Metabolites were separated under isocratic conditions using 19% of 15 mM ammonium formate 
with 0.1% formic acid and 81% acetonitrile with flow of 0.5mL/min. Assay impression was less 
than 5% for each metabolite based on in-house human plasma controls. 
Macular Pigment Optical Density (MPOD)  
MPOD was assessed via a customized hetero-flicker photometry (cHFP) technique 
administered using a macular densitometer (Macular Metrics Corporation, Rehoboth, MA, USA). 
The principles of this technique have been previously described 136–138. Briefly, participants were 
asked to view stimuli peaking at a wavelength of 460 nm that flickers in counter phase with a 570 
nm reference. Trained members of the research staff adjusted the radiance of the stimuli and 
participants were asked to identify a null flicker zone by informing the operator when they could 




parafoveally fixated. The MPOD score, with standard deviation, was calculated by subtracting the 
foveal from the parafoveal log sensitivity measurements after normalization at 570 nm. 
Switch Task 
Cognitive Flexibility was assessed using a Switch task that has been described previously 
111. Briefly, participants completed two blocks of homogeneous trials, in which they learned and 
practiced two basic rule sets with a test block of 90 jittered trials with an inter-stimulus interval 
(ISI) of either 1600, 1800, or 2000 ms. One subsequent heterogeneous condition was then 
completed, where participants were required to flexibly switch between the previously learned rule 
sets for a practice block of 50 trials, and 200 trials of randomized stimuli with similarly jittered 
ISI. A “Switch” trial was defined as a trial in which the previous stimuli belonged to a different 
mental rule set than the one presented. A “NonSwitch” trial was defined as a trial in which the 
previous stimuli belonged to the same mental rule set as the stimuli presented. Measures of 
accuracy and RT for homogeneous and heterogeneous blocks, and for both Switch and NonSwitch 
trials of the heterogeneous block, were assessed. Local Switch Cost for accuracy was calculated 
as NonSwitch accuracy – Switch accuracy, and for RT as Switch RT – NonSwitch RT. Global 
Switch Cost for accuracy was calculated as overall accuracy of the homogenous trials – overall 
accuracy of the heterogeneous trials, and for RT as overall RT of the heterogeneous trials – overall 
RT of the homogenous trials. 
Event-related potential Analysis 
EEG activity was recorded via a Neuro-scan Quik-cap with 64 scalp electrodes arranged 
in the international 10-10 system 107. Electrooculographic activity was recorded with a set of four 




sensor placed between Cz and CPz served as a reference and AFz served as the ground. Further 
explanation of reduction procedures have been previously published 111.  
Based on evidence observed from post-hoc topographic images, sensor FCZ was utilized 
for N2 assessment, and a 6-sensor region of interest (ROI) comprised of C1, CZ, C2, CPZ, CP1, 
and CP2 electrodes was utilized for P3 assessment. Only correct trials from individuals who 
reported >50% usable trials in both homogenous and heterogeneous trial types were used for 
analyses. The N2 component was defined as the localized peak and corresponding latency 
occurring between 150-300 ms post-stimulus onset, and the P3 component was defined as the 
localized peak and corresponding latency occurring between 300-600 ms post-stimulus onset. Peak 
amplitude was measured as a change score from the pre-stimulus baseline and peak latency was 
defined as the time point of the maximum amplitude. 
Dietary Intake 
Analyses of 7-day dietary records were conducted using the 2015 Nutrition Data System 
for Research (NDSR) software (Nutrition Coordinating Center, University of Minnesota, 
Minneapolis, MN, USA). Diet records were administered and entered into NDSR by trained 
members of the research staff. Within NDSR, as with most nutrient databases, lutein and 
zeaxanthin are aggregated. Thus, lutein intake refers to the joint intake of lutein and zeaxanthin. 
Choline intake in NDSR refers to the combined intake of free choline, phosphocholine, PC, 
glycerophosphocholine, as well as sphingomyelin. Average lutein and choline intake over the 7-
day period was assessed using the averages of the NDSR Intake Properties Totals Output File (04). 
Statistical Analysis 
The Statistical Package for the Social Sciences (SPSS, version 24, IBM, Armonk, New 




normality, as assessed through graphical methods (Q-Q plots) or with p<0.05 as assessed by 
Shapiro-Wilk, were log transformed and normality was reassessed. Independent t-tests were 
conducted to examine differences between males and females, with significance set at p<0.05. 
Initial Pearson product-movement bivariate correlations were conducted between dietary 
components (lutein, choline), serum lutein concentrations, MPOD, and plasma concentrations of 
free choline and PC. To assess the interactions of independent variables, interaction terms were 
calculated as the product of the two independent variables of interest. Interaction terms produced 
were 1) dietary lutein x dietary choline, 2) plasma PC x plasma free choline, 3) plasma PC x 
MPOD, and 4) plasma PC x serum lutein. Potential multicollinearity was evaluated utilizing 
variance inflation factors with a cut-off >2. Variables that displayed multicollinearity were mean 
centered by subtracting the sample mean from each variable, and the centered variables were used 
in further analyses. To address the differences in individual and interactive contributions of 
independent variables on measures of cognitive flexibility, data were subjected to hierarchical 
linear regression analyses, with cognitive flexibility outcomes as dependent factors. Step 1 
consisted of pertinent demographic and weight status variables (age, sex, BMI, IQ, and household 
income), and Step 2 contained two independent variables of interest as well as the interaction term. 
R2 and Akaike Information Criteria (AIC) were used to assess model fit. To determine the 
unique contribution of each predictor variable, the squared semipartial correlations were utilized. 
For models in which the centered interaction term was significant simple slopes models were 
produced. The simple slope procedure takes the low value of a variable (in this case the lowest 
tertile of dietary choline intake), the mean value of a variable (the second tertile of dietary choline 
intake), and a high value of a variable (the third tertile of dietary choline intake) and determines 




second variable. This modeling provides an analysis of the significant interaction terms by plotting 
the direction and rate of change at each level of the first variable139. 
Results 
Correlations between Dietary Intake and Biomarkers 
Full descriptions of dietary intake and biomarker concentrations are depicted in Table 7.1. 
Full bivariate correlation results are described in Table 7.2. Dietary lutein intake was correlated 
with dietary choline intake (r=0.35, p<0.01) and serum lutein concentrations (r=0.42, p<0.01). 
Dietary choline intake was correlated with serum lutein concentrations (r=0.35, p<0.01). MPOD 
was correlated with serum lutein concentrations (r=0.32, p<0.01). Neither plasma PC 
concentrations, nor plasma free choline concentrations, were correlated with dietary measures of 
either lutein or choline, nor measures of serum lutein nor MPOD concentrations (all p’s>0.05). 
Cognitive task performance 
Age, sex, BMI, IQ, and household income were entered into Step 1 for each model. Full regression 
values including standardized regression coefficients, independent variable significance, ΔR2, 
model significance, and squared semipartial correlations can be found in Tables 7.3 and 7.4. 
Dietary Intake 
Multicollinearity between dietary and metabolite data was observed for all independent 
variables (all VIF’s>2.0, range=4.5-565.7). After centering of variables all issues of 
multicollinearity were resolved (all VIF’s<2.0, range=1.1-1.5). Step 2 included the addition of 




Table 7.1. Demographic characteristics, weight status, dietary intake, and Switch variables¹ 
  Value 
 Group Female Male 
N 80 48 32 
Age, y 34.7 ± 5.9 35.0 ± 6.1 34.3 ± 5.7 
Intelligence Quotient 109.2 + 11.8 107.9 ± 11.7 110.9 ± 11.9 
Body Mass Index, kg/m²,² 33.0 ± 6.5 34.1 ± 6.5 31.4 ± 6.3 
Dietary Choline, mg/day 353.3 ± 111.1** 317.6 ± 93.9 406.9 ± 114.6 
Dietary Lutein + Zeaxanthin, mg/day 1.55 ± 1.13 1.54 ± 1.18 1.56 ± 1.07 
Serum Lutein, μmol/L 0.12 ± 0.06 0.12 ± 0.05 0.12 ± 0.06 
Macular Pigment Optical Density 0.44 ± 0.21 0.44 ± 0.20 0.45 ± 0.22 
Plasma Phosphatidylcholine, μmol 2.15 ± 0.29 2.16 ± 0.30 2.13 ± 0.27 
Plasma Free choline, nmol 8.12 ± 1.87* 8.45 ± 1.98 7.54 ± 1.55 
Homogeneous Accuracy, % 95.0 ± 4.4 95.09 ± 3.92 94.90 ± 5.03 
Homogeneous RT, ms 516.9 ± 69.2 514.8 ± 55.3 520.0 ± 86.9 
Heterogeneous Accuracy, % 80.8 ± 10.6 80.4 ± 11.2 81.3 ± 9.9 
Heterogeneous RT, ms 770.4 ± 100.9* 748.4 ± 98.8 803.5 ± 96.3 
NonSwitch Accuracy, % 84.2 ± 11.0 83.6 ± 12.3 85.2 ± 8.9 
NonSwitch RT, ms 720.7 ± 89.8** 699.1 ± 84.8 753.2 ± 88.4 
Switch Accuracy, % 77.4 ± 11.5 77.3 ± 11.5 77.5 ± 11.5 
Switch RT, ms 825.2 ± 122.7* 802.6 ± 122.5 859.1 ± 116.8 
Annual Household Income, %    
<$10,000-$40,000 33 25 28 
$41,000-$80,000 35 44 31 
$81,000+ 32 31 41 
¹ Values are means ± SD unless otherwise stated 
² Determined by the Center for Disease Control Body Mass Index (BMI) classifications 
* Significant differences between sexes (p > 0.05) 







Table 7.2. Bivariate correlations between dietary intake lutein and choline, serum lutein concentrations, phosphatidylcholine and 









Phosphatidylcholine Free choline MPOD 
Dietary Lutein - - - - - - - 
Dietary Choline 0.35** - - - - - - 
DIT 0.93** 0.67** - - - - - 
Serum Lutein 0.42** 0.35** 0.47** - - - - 
Phosphatidylcholine 0.01 0.01 0.01 0.15 - - - 
Free choline 0.12 -0.01 0.09 -0.04 -0.11 - - 
MPOD 0.03 0.11 0.06 0.32** -0.18 0.12 - 
**Correlation is significant at the 0.01 level (2-tailed).    
*Correlation is significant at the 0.05 level (2-tailed). 




 (Table 7.3). The addition of these variables improved the model for NonSwitch RT ((ΔR²=0.10, 
ΔAIC=-3.99, p=0.03), Switch RT (ΔR²=0.10, ΔAIC=-2.79, p=0.05), and Global Switch Cost 
(ΔR²=0.08, ΔAIC=-2.74, p=0.05). Dietary lutein and dietary choline were not independently 
related to measures of RT nor accuracy (all p>0.05); however, the dietary interaction term was 
associated with faster RT in both NonSwitch (β=-0.27, p=0.02) and Switch (β=-0.29, p=0.01) 
trials, as well as the Global Switch Cost (β=-0.23, p=0.03). Within these models, the dietary 
interaction term also accounted for the largest percentage of variance explained by the dietary 
contributors, at 6.4% for NonSwitch RT, 7.5% for Switch RT, and 4.8% for Global Switch Cost. 
Centered dietary lutein, centered dietary choline, and their interaction term were not related to 
accuracy in any task trials (all p’s>0.05). Figures 7.1-7.3 illustrate the plotted simple slope models 
of these interactions. 
PC and free choline 
For these analyses, Step 2 included the addition of centered plasma PC concentrations, 
centered plasma free choline concentrations, and their multiplicative interaction term (Table 7.4). 
The addition of these variables improved the model for Switch trial accuracy (ΔR²=0.08, ΔAIC=-
2.10, p=0.05). In this model, plasma PC concentrations were associated with higher task accuracy 
(β=0.27, p=0.02), while plasma free choline concentrations, and the interaction of plasma PC 
concentrations and plasma free choline were not significant (all p>0.05). PC concentration 
accounted for 6.6% of the variance explained by the metabolite contributors. Plasma PC, plasma 







Table 7.3. Linear Regression between pertinent covariates, dietary lutein, dietary choline, their interactive term, Switch task outcomes. 
  NonSwitch RT Switch RT Global Switch Cost RT 
Step and 
Variable β p ΔR² 
Model 
P sr² β p ΔR² 
Model 
P sr² β p ΔR² 
Model 
P sr² 
Step 1                               
Sex 0.29** 0.01 
0.15* 0.03 
7.98 0.21 0.06 
0.16* 0.02 





-0.13 0.91 0.02 0.00 0.99 0.00 0.03 0.81 0.06 
Intelligence 
Quotient 
-0.11 0.33 1.09 -0.07 0.55 0.42 0.02 0.85 0.04 
Age -0.07 0.56 0.39 -0.14 0.25 1.56 -0.13 0.27 1.22 
Household 
Income 





Step 2                    
Centered Lutein 0.14 0.24 
0.10* <0.01 
1.48 0.09 0.44 
0.09* <0.01 





0.13 0.32 1.06 0.07 0.55 0.38 0.04 0.76 0.09 
Interaction 
-0.27* 0.02 6.38 -
0.29** 
0.01 7.46 -0.23* 0.03 4.78 
**Relationship is significant at the 0.01 level (2-tailed).          
*Relationship is significant at the 0.05 level (2-tailed).          














Table 7.4.  Linear Regression between pertinent covariates, plasma phosphatidylcholine, plasma free choline, their interactive term, Switch task 
outcomes. 
  Homogeneous Accuracy NonSwitch Accuracy Switch Accuracy 
Step and 
Variable β p ΔR² 
Model 
P sr² β p ΔR² 
Model 
P sr² β p ΔR² 
Model 
P sr² 
Step 1                               








0.12 -0.04 0.73 
0.12 0.08 
0.14 
Body Mass Index -0.07 0.54 0.45 0.16 0.13 2.35 0.03 0.80 0.08 
Intelligence 
Quotient 









0.00 9.79 0.21 0.07 3.45 0.11 0.38 0.93 





2.88 0.14 0.19 
0.02 <0.01 







0.02 0.86 0.04 0.07 0.53 0.41 -0.03 0.82 0.06 
Centered 
Interaction 
0.13 0.25 1.57 0.05 0.65 0.22 0.14 0.20 1.85 
**Relationship is significant at the 0.01 level (2-tailed).        
*Relationship is significant at the 0.05 level (2-tailed).      




PC and Serum Lutein concentrations 
For these analyses, Step 2 included the addition of centered plasma PC concentrations, 
centered serum lutein concentrations, and their multiplicative interaction term. The addition of 
these variables improved the model for Switch accuracy (ΔR²=0.07, ΔAIC=-2.10, p=0.05). In the 
significant model for Switch accuracy, plasma PC concentrations were associated with higher task 
accuracy (β=0.24, p=0.04), while serum lutein concentrations, and the interaction of plasma PC 
and serum lutein concentrations was not significant (all p>0.05). Plasma PC concentration 
accounted for 5.5% of the variance explained by the metabolite contributors. Plasma PC 
concentration and serum lutein concentration were not related to RT in any task trials (all p>0.05). 
 
PC and MPOD 
For these analyses, Step 2 included the addition of centered plasma PC concentrations, 
centered MPOD, and their multiplicative interaction term. The addition of these variables 
improved the model for Switch accuracy (ΔR²=0.07, ΔAIC=-0.68, p=0.04) and Local Switch Cost 
accuracy (ΔR²=0.11, ΔAIC=-4.16, p=0.03). In the significant model for Switch accuracy, plasma 
PC concentrations were associated with higher accuracy (β=0.28, p=0.02) while MPOD, and the 
interaction term were not (all p’s>0.05). Plasma PC concentration accounted for 6.5% of the 
variance explained by these contributors. In the significant model for Local Switch Cost accuracy, 
plasma PC concentrations were associated with lower accuracy cost (β=-0.28, p=0.02) when 
alternating between NonSwitch and Switch trials, as was the interaction term (β=-0.28, p=0.02). 
Plasma PC concentrations accounted for 6.8% of the variance explained by these contributors, 
while the interaction term accounted for 6.1%. Plasma PC concentration and MPOD were not 





None of the models were predictive of N2 nor P3 peak amplitude or latency variables in 
either the homogenous or heterogeneous task conditions, nor in terms of Global or Local Switch 
Costs (all p>0.05). Therefore, while relationships were observed between variables of interest and 
behavioral accuracy and RT, there was a lack of a mechanistic explanation to be derived from 
underlying neuroelectric responses. Waveform depictions are presented in Figure 7.4. 
 
Discussion 
This study aimed to examine the associations between dietary intake of lutein and choline, 
biomarkers of serum lutein, macular pigmentation, plasma PC and plasma free choline, and their 
individual and interactive effects on cognitive flexibility among a sample of middle-aged adults 
with overweight and obesity. Dietary intake of lutein and choline was associated with higher serum 
lutein concentrations, and not with MPOD, plasma PC, or plasma free choline. Independently, 
dietary lutein and dietary choline were not related to RT nor accuracy in a cognitive flexibility 
task; however, even after controlling for pertinent demographic and weight status covariates, 
higher interactive consumption was associated with faster RT in the more cognitively demanding 
trial types. Among metabolites, PC concentrations were related to higher accuracy on Switch trial 
types, while neither serum lutein concentrations, MPOD, plasma free choline concentrations, nor 
their interactions with plasma PC concentrations, were related with cognitive flexibility. These 
results point to an interactive role of dietary intake of lutein and choline on cognitive flexibility 





In this study, we observed associations between dietary intake of the xanthophyll 
carotenoid lutein and the vitamin choline. Both dietary lutein and dietary choline were related to 
serum lutein concentrations, perhaps explained by simultaneous presence of these components in 
the gastrointestinal tract at time of digestion and the known interactive properties of absorption 
63,140. Choline contributes to lipid transport throughout the body, particularly to lipoprotein 
production in the liver. It is possible that with higher choline intake there is increased lipoprotein 
production, which are the primary source of lutein transportation throughout the body, resulting in 
higher serum lutein concentrations 141. Dietary intake of lutein and choline were not related to 
choline metabolite concentrations, nor MPOD. Null associations between concurrent choline 
intake and metabolite status is supported in the literature, as choline serves a wide array of roles 
throughout the body 41,56,142. Serum lutein concentrations were correlated with MPOD, perhaps 
suggesting that serum lutein concentrations are more susceptible to acute dietary intake than retinal 
accumulation 143. 
While both lutein and choline have been independently related to benefits for cognitive 
control, we did not observe benefits of individualized consumption in the present study. Further, 
faster processing speed, as evidenced by faster RT, was only observed with the interaction of the 
two components (i.e., lutein and choline)106. Within the brain, lutein serves as one of several anti-
oxidants, and choline (derived from the diet or endogenous production) can serve as a precursor 
for the neurotransmitter acetylcholine (ACh)48,49. ACh has been demonstrated to influence 
neuronal excitability, alter presynaptic release of neurotransmitters, and coordinate the firing of 
groups of neurons 64. In rodent models, high acetylcholinesterase (the enzyme that catalyzes 
breakdown of ACh) activity in the hippocampus and cortex has been associated with ethanol-




activity and ethanol-induced memory impairment compared to a control group 65. Notably, a 
limitation of clinical research is the inability to evaluate concentrations of cerebral ACh. It is 
possible that the benefits derived from combined consumption of lutein and choline are due to an 
increase in cerebral ACh production, driven perhaps by lutein’s attenuation of acetylcholinesterase 
activity and high amount of choline intake.  
Within the human literature, to our knowledge, only one study has previously examined 
the interactive influence of these dietary components 66. Among an infant cohort, Cheatham et. al. 
observed that higher combined intake of choline and lutein from breastmilk was predictive of faster 
latency to peak amplitude in a recognition memory task as assessed using ERPs. While the present 
study observed faster behavioral RT during a cognitive flexibility task, contrary to our hypotheses 
we did not observe relationships between peak amplitude nor latency of the N2 and P3 components 
and independent variables of interest. This lack of statistical significance provides information on 
the alternative neural mechanistic benefits that may occur with lutein and choline consumption in 
middle-age adults. ERPs are measurements of post-synaptic potentials from cortical pyramidal 
cells, emitted by cumulative changes in synaptic ionic activity due to the binding of 
neurotransmitters, such as ACh, to their receptors 102. Cognitive flexibility, in particular, is reliant 
upon activation of mental rule-sets, which are contingent upon exogenous stimuli cuing (in this 
case, through the dashed or solid boxes). RT as measured by a behavioral response incorporates a 
number of cognitive processes, including but not limited to, response selection, response 
execution, and stimulus evaluation, and is not consistently related to latency or peak amplitude 144. 
The N2 is most notably associated with the inhibition of response selection, while the P3 is 
indicative of stimulus evaluation and categorization. The present null relationships indicate that 




categorization factors 102. Future studies utilizing follow-up methods of neuroimaging should thus 
be conducted. 
In regard to the relationship between biomarker status and cognition, solely PC 
concentrations were related to benefits for cognitive flexibility, specifically accuracy within the 
Switch trials. It is important to note that within the present study, PC concentrations were assessed 
peripherally and were not derived from brain cortices. Nonetheless, circulating PC concentrations 
have been found to be lower in patients with Alzheimer’s Disease (AD), and alterations in 
peripheral and brain PC/lipid metabolism among patients with AD have been demonstrated 47,48. 
These findings allude to a potential benefit of circulating PC for cognitive health, though testing 
of this relationship has been problematic due to heterogeneity of both results and testing methods. 
In elderly patients with AD, higher concentrations of free choline have been observed within the 
brain 49. These higher concentrations of free choline have been interpreted as a marker of 
neurodegeneration, in what has been referred to as “autocannabalism” – or the brains degenerating 
attempts to release choline from its largest storage site (PC) and compensate for the characteristic 
lack of free choline and ACh 49. Much of current AD treatment is based around this choline deficit, 
through the use of cholinergic agonists to promote choline production and preserve cell membrane 
integrity 50. The present results are suggestive of a perhaps similar role for circulating PC in 
cognitive health in middle adulthood. 
 While this study derived its strengths from the use of neuroelectric and behavioral 
paradigms and utilized both dietary assessments as well as biomarkers of dietary intake to 
objectively measure serum lutein and choline concentrations, it is not without limitations. First, 
these results are cross-sectional, and thus relationships observed should be interpreted without the 




obesity, and thus may not be extrapolated to those of healthy weight status. Though, given that 
70% of the American population currently suffers from overweight or obesity, this sample is more 
generalizable than a healthy weight sample. The dietary data provided included aggregated 
quantification of dietary lutein and zeaxanthin intake, therefore we are unable to separate the 
impact of the two xanthophylls on cognitive function. Lastly, the dietary data provided was based 
on self-report measures. Though detailed instructions were given on proper dietary recording by 
trained members of the research staff, it is possible that participants may have over or 
underestimated foods and ingredients consumed.  
 
Conclusion 
 After controlling for age, sex, BMI, IQ, and household income, middle-aged participants 
with overweight or obesity exhibited faster RT during a cognitive flexibility task with greater 
dietary consumption of lutein and choline. Consumption of these dietary components was also 
related to higher serum lutein concentrations, but was not related with MPOD, plasma PC 
concentrations, plasma free choline, nor measures of neuroelectric components. Future studies are 
necessary to further elucidate the potential interactive properties of dietary components such as 






























Figure 7.1. Simple slopes model of dietary lutein by choline interaction for reaction 
time (RT) in the NonSwitch Trials of a Switch Task. Negative values are indicative of 
faster RT. Choline intake was split into tertiles, with average tertile intake of 231.9 mg 


















Figure 7.2. Simple slopes model of dietary lutein by choline interaction for reaction time 
(RT) in the Switch Trials of a Switch Task. Negative predicted values are indicative of 
faster RT. Choline intake was split into tertiles, with average tertile intake of 231.9 mg in 















Figure 7.3. Simple slopes model of dietary lutein by choline interaction for reaction 
time (RT) in the Global Switch Trials of a Switch Task. Negative predicted values are 
indicative of faster RT. Choline intake was split into tertiles, with average tertile 
intake of 231.9 mg in the lowest tertile, 329.6 in the middle tertile, and 481.4 in the 







Figure 7.4: Event-related potential waveform depictions of the P3 component.  The sample underwent a median split of a 
multiplicative dietary lutein x dietary choline interaction term into Low and High groups for visualization of a) Switch Trials and b) 








































CHAPTER 8: CONCULSIONS AND FUTURE DIRECTIONS 
The dietary components lutein and choline have been hypothesized to play a protective role 
in cognitive health across the lifespan, and have been cross-sectionally associated with decreased 
risk of dementia and AD47,48,145.  Dietary intake of beneficial dietary components may provide a 
feasible strategy to preserving cognitive health during across the lifespan, particularly among 
adults with overweight and obesity. Therefore, the specific aims of this work were to utilize a 
sample of adults with overweight and obesity to: 1) Cross-sectionally, and through a randomized 
controlled trial, examine the role of retinal xanthophyll accumulation and serum lutein status on 
behavioral and neuroelectric components of cognitive control, 2) Cross-sectionally examine the 
role of choline intake on behavioral and neuroelectric components of cognitive control, and 3) 
Cross-sectionally examine the independent and interactive roles of choline and lutein intake and 
choline and lutein concentrations on cognitive control. This was accomplished utilizing both 
baseline and intervention data from a large-scale clinical trial investigating the impact of avocado 
consumption on measures of behavioral and neuroelectric indices of cognitive control.   
 
Summary of Aims and Findings 
Aim 1. We demonstrated that, as hypothesized, higher MPOD was cross-sectionally associated 
with higher neural efficiency in both the N2 and P3 ERP components, though behavioral 
improvements were not observed. To assess the impact of lutein intake on MPOD and 
neuroelectric indices of cognitive control we conducted a 12-week avocado consumption 
randomized controlled trial. In this trial, we observed increases in serum lutein concentrations and 
improvements in selective attention performance in the intervention group, but no changes in 




Aim 2. We demonstrated that higher dietary intake of choline was associated cross-sectionally to 
increased neural efficiency as indexed by the P3 component, though behavioral improvements 
were not observed. 
 
Aim 3. We demonstrated that higher dietary intake of both lutein and choline, when compared to 
independent consumption of lutein and independent consumption of choline, was associated cross-
sectionally with improvements in reaction time in a cognitive flexibility task, though associations 
with ERP components were not observed. 
 
Limitations and Future Work 
 Plans for moving forward with this work are currently underway through additional data 
analyses by other team members, and through the initiation of an egg-based randomized controlled 
trial aimed at examining a whole-food source of lutein and choline intake on measures of cognitive 
control. While the work described thus far contributes to the growing literature emphasizing the 
importance of studying dietary components within the context of cognitive health, there is still 
research needed. Several limitations are worth considering when interpreting these findings, 
notably utilization of self-report data, the use of a sample of solely adults with overweight and 
obesity, and the cross-sectional nature of a number of the current findings. 
 There is a frequent prevalence of under and over reporting of self-report dietary intake, 
particularly among adults with overweight and obesity146. To address this concern, whenever 
possible the authors attempted to include a reliable biomarker of said dietary intake in analyses for 
validation (ex.: MPOD). The 7-day diet records used in Aims 2 and 3 were deployed by graduate 




by trained members of the research staff, and were then statistically analyzed for outliers ≥ 3 
standard deviations outside of group means. While the methods used to collect the presently 
presented data have been previously validated, moving forward with other methods of assessing 
dietary intake could provide insight, and confirmation of these results. Future work aiming to 
replicate these findings would benefit from using 7-day diet records in conjunction with novel 
technology. 
 While using the human model to examine the direct impact of a dietary components on 
cognitive outcomes has several significant strengths, one limitation is the lack of currently 
available preclinical techniques of testing these hypotheses. While there are excellent studies 
examining brain tissue samples in deceased pediatric as well as geriatric populations, currently 
there are no studies that have been able to directly examine the presence of, or potential actions of, 
lutein and choline in a middle-aged population17,147. Lutein and zeaxanthin do not accumulate 
within the retina of mice, pigs, or rodents; therefore, animal work has been largely limited to using 
non-human primate samples as primates do accumulate lutein and zeaxanthin in the retina20. This 
presents obstacles to understanding the mechanistic action that lutein or choline may have crossing 
the blood brain interface and accumulating and acting within brain cortices. Future work in non-
human primates as well as development of additional methods of assessing nutrient biomarkers in 
living humans is thus warranted. 
 Lastly, while in Aim 3 we were able to observe statistically significant interactions between 
lutein and choline dietary intake and measures of response time, this was done cross-sectionally 
and analyses were post-hoc. Future replication work is needed both in cross-sectional work as well 
as randomized-controlled trials utilizing a priori hypotheses about the interactive nature of dietary 
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